[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Breg Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":237},{"warningLetters":4,"total":236},[5,31,52,68,85,98,116,137,157,180,198,220],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},890,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-05-20T04:00:00Z\">05\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-18T05:00:00Z\">11\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbreadbox-co-686647-11182024\">Breadbox Co.\u003C\u002Fa>","Human Foods Program","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated\u002FInsanitary Conditions","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Mehran Termechi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner &amp; Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Breadbox Co.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10603 Painter Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Santa Fe Springs\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90670\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ron.melrosebaking@gmail.com\"> ron.melrosebaking@gmail.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 18, 2024\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS # 686647\u003C\u002Fp>\u003Cp>Dear Mr. Termechi,\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your human food manufacturing facility, located at 10603, Santa Fe Springs, CA, from May 10 through June 7, 2024. During the inspection, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food Regulations (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\u003C\u002Fp>\u003Cp>Based on FDA’s inspectional findings, we have determined that the ready-to-eat (RTE) bakery products manufactured in your facility are adulterated within the meaning section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and FDA’s regulations through links on FDA’s homepage at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, FDA investigators issued a Form FDA 483 (FDA-483), Inspectional Observations, listing the deviations found at your facility. To date, FDA has not received a written response to the inspection. After reviewing the inspectional findings, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Hazard Analysis and Risk-Based Preventive Controls Requirements (21 CFR Part 117, Subpart C)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Col>\u003Cli>You did not prepare, or have prepared, and implement a food safety plan, as required by 21 CFR § 117.126(a)(1). The preparation of the food safety plan must be overseen by one or more preventive controls qualified individuals (PCQIs), as required by 21 CFR § 117.126(a)(2). Your food safety plan must also include the following:\u003Cbr>I. The written hazard analysis, as required by 21 CFR § 117.130(a)(2);\u003Cbr>II. The written preventive controls, as required by 21 CFR § 117.135(b);\u003Cbr>III. The written supply-chain program, as required by Subpart G;\u003Cbr>IV. The written recall plan, as required by 21 CFR § 117.139(a);\u003Cbr>V. The written procedures for monitoring the implementation of the preventive controls, as required by 21 CFR § 117.145(a);\u003Cbr>VI. The written corrective action procedures, as required by 21 CFR § 117.150(a)(1); and\u003Cbr>VII. The written verification procedures, as required by 21 CFR § 117.165(b).\u003C\u002Fli>\u003C\u002Fol>\u003Cp>Your facility manufactures a variety of RTE bakery products, including but not limited to breads muffins, cookies, croissants, and bagels. However, you did not have a food safety plan with any of the required elements for any of the products manufactured by your facility. For example, you did not conduct a hazard analysis to identify and evaluate known or reasonably foreseeable hazards for each type of food manufactured, processed, packed, or held at your facility to determine whether there are any hazards requiring a preventive control (see 21 CFR § 117.130(a)). Also, you did not identify and implement preventive controls to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented and the food manufactured, processed, packed, or held by your facility will not be adulterated under section 402 of the Act or misbranded under section 403(w) of the Act (see 21 CFR § 117.135(a)(1)). Preventive controls include, as appropriate to the facility and the food, process controls, food allergen controls, sanitation controls, supply-chain controls, and a recall plan (see 21 CFR § 117.135(c)). Preventive controls are subject to preventive control management components (monitoring, verification, and corrective actions) as appropriate to ensure the effectiveness of the preventive controls, taking into account the nature of the preventive control and its role in the facility's food safety system (see 21 CFR § 117.140). You must also validate that the preventive controls are adequate to control the hazard as appropriate to the nature of the preventive control and its role in the facility’s food safety system (see 21 CFR § 117.160). Specifically:\u003C\u002Fp>\u003Cp>a. You did not identify and evaluate allergens as a known or reasonably foreseeable hazard to determine whether allergens are a hazard requiring a preventive control (see 21 CFR § 117.130(b)(1)(ii)). Your facility manufactures more than 1900 bakery products that contain allergens (such as wheat, soy, milk, eggs, tree nuts (e.g., almonds) and sesame). These products containing different allergen profiles are processed on shared equipment using shared utensils on the same production day. Therefore, allergens are a known or reasonably foreseeable hazard. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify allergens as a hazard requiring a preventive control. Food allergen controls include procedures, practices, and processes employed for ensuring protection of food from allergen cross-contact (including during storage, handling, and use) and for labeling to ensure that all food allergens required to be stated are included on the label (see 21 CFR § 117.135(c)(2)).\u003C\u002Fp>\u003Cp>You do not have controls in place for the hazard of allergen cross-contact, as evidenced by the following:\u003C\u002Fp>\u003Cp>i. On May 15, 2024, sesame seeds were observed embedded on the surfaces of breadsticks in at least two bags of Breadman Breadsticks (15 oz - finished product produced on May 14, 2024). The Breadman Breadsticks do not include sesame seeds as ingredients. Furthermore, on May 23, 2024, sesame seeds were observed embedded on the surfaces of breadsticks in at least two bags (unlabeled, bulk order, finished product) of breadsticks, where the ingredients do not include sesame seeds.\u003C\u002Fp>\u003Cp>ii. On May 10, 2024, one of your production employees was observed using a mixer to make dough for Brioche (which contains wheat, egg, and unsalted 70% vegetable oil spread (soy lecithin, milk)). After the \u003Cstrong>(b)(4)\u003C\u002Fstrong> step, the production employee cleaned the mixer by scraping the excess dough from the interior of the mixer bowl and wiping it with a wet fabric cloth. Yellow, egg-like food residue, from the Brioche dough, remained on the interior of the mixer bowl. The same mixer bowl was then used to make dough for the Torpedo product which does not contain the soy or egg allergen ingredients.\u003C\u002Fp>\u003Cp>b. For your RTE bakery products, you did not identify and evaluate undeclared color additives as a reasonably foreseeable hazard to determine whether they are a hazard requiring a preventive control (see 21 CFR § 117.130(b)(1)(ii)). Your facility manufactures products containing the color additive FD&amp;C Yellow #5. FD&amp;C Yellow #5 is known to cause adverse reactions in sensitive individuals, including bronchial asthma in asthmatic individuals. Therefore, undeclared FD&amp;C Yellow #5 is a known or reasonably foreseeable hazard. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify undeclared FD&amp;C Yellow #5 as a hazard requiring a preventive control. Preventive controls include procedures, practices, and processes necessary to ensure that food manufactured processed, packed, or held by your facility will not be adulterated under section 402 or misbranded under section 403(w) (see 21 CFR 117.135(a)(1) and 21 CFR 117.135(c)(6)), such as during receipt of labels and during packaging\u002Flabeling operations, to ensure FD&amp;C Yellow #5 is declared for products containing this color additive. You do not have controls in place, as evidenced by the following:\u003C\u002Fp>\u003Cp>i. On May 14, 2024, your facility manufactured Breadman Raisin Bread, which contains butter essence (FD&amp;C Yellow #5) and egg shade liquid color (FD&amp;C Yellow #5). However, the finished product label, which you distributed on May 15, 2024, did not declare FD&amp;C Yellow #5 on the ingredients list. You recalled this product on May 16, 2024.\u003C\u002Fp>\u003Cp>ii. On May 14, 2024, your facility manufactured Brioche, which contains butter essence (FD&amp;C Yellow #5) and egg shade liquid color (FD&amp;C Yellow #5) and distributed them to your bulk-order customers (i.e., restaurants, hotels, etc.). However, the Ingredient &amp; Allergen Statement that you sent to your bulk-order customers did not declare FD&amp;C Yellow #5. Additionally, you do not include the Ingredient &amp; Allergen Statement with every delivery of bulk orders to customers. The customer only receives the statement with the initial bulk order. You distributed the Brioche on May 15, 2024 and later recalled it on May 16, 2024.\u003C\u002Fp>\u003Cp>c. For your RTE bakery products, you did not identify and evaluate recontamination with environmental pathogens, such as Salmonella, as a known or reasonably foreseeable hazard to determine whether it is a hazard requiring a preventive control, to comply with 21 CFR § 117.130(c)(1)(ii). Your facility manufactures RTE bakery products which are exposed to the environment after they exit the oven, such as while they are cooled prior to packaging. The packaged food does not receive any further lethal treatment or otherwise include a control measure (such as a formulation lethal to the pathogen) that would significantly minimize the pathogen. Therefore, recontamination with environmental pathogens is a known or reasonably foreseeable hazard. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify contamination with environmental pathogens as a hazard requiring a preventive control. Sanitation controls include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens and biological hazards due to employee handling (see 21 CFR § 117.135(c)(3)). In addition, note that environmental monitoring is required if contamination of an RTE food with an environmental pathogen is a hazard requiring a preventive control (see 21 CFR § 117.165(a)(3)). You do not have controls in place for contamination with environmental pathogens, as evidenced by the following:\u003C\u002Fp>\u003Cp>i. On May 14, 2024 and May 15, 2024, loaves of RTE bread were observed stored directly on metal racks with heavily encrusted grease and debris build-up, to be packaged and distributed to customers. These racks were in the RTE packaging area.\u003C\u002Fp>\u003Cp>ii. On May 23, 2024, loaves of RTE whole wheat bread and RTE squaw bread were observed cooling directly on the same dirty metal racks in the baking room.\u003C\u002Fp>\u003Cp>iii. On May 14, 2024, a production employee was observed removing loaves of RTE squaw bread from metal pans and placing them on a metal rack in the baking room using a pair of soiled fabric mittens. The soiled fabric mittens touched the loaves of RTE squaw bread. These same mittens were also used to handle oven doors and metal carts after baking. Additionally, on May 23, 2024, another production employee was observed removing loaves of RTE wholewheat bread from metal pans and placing them on a metal rack in the baking room using a pair of soiled fabric mittens. The soiled fabric mittens touched the loaves of RTE whole wheat bread.\u003C\u002Fp>\u003Cp>iv. Your facility does not have an environmental monitoring program to monitor for environmental pathogens.\u003C\u002Fp>\u003Cp>d. You did not identify and evaluate mycotoxins as a known or reasonably foreseeable hazard to determine whether they require a preventive control (see 21 CFR § 117.130(b)(1)(ii)). Your facility manufactures RTE bakery products that contain wheat flour and tree nuts (e.g., almonds). These ingredients have been associated with mycotoxins. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify mycotoxins as a hazard requiring a preventive control in these ingredients. Further, a facility that identifies raw materials and other ingredients that require a supply-chain-applied control, such as mycotoxins, must establish and implement a risk-based supply-chain program for those raw materials and ingredients (see 21 CFR § 117.405(a)(1)). The supply-chain program must include using approved suppliers and conducting supplier verification activities (see 21 CFR § 117.410). You do not have this program in place.\u003C\u002Fp>\u003Cp>e. For your RTE bakery products, you did not establish a written recall plan. Your RTE bakery products have multiple known or reasonably foreseeable hazards requiring preventive controls (see 21 CFR § 117.139(a). On May 16, 2024 your facility initiated a recall of your Breadman Raisin Bread, Jalapeno Cheese Bagels and Breadman Brioche products due to the lack of proper allergen declarations and the food coloring ingredient FD&amp;C Yellow #5 on finished product labeling.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Current Good Manufacturing Practices Requirements (21 CFR Part 117, Subpart B)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>2. Your equipment and utensils used in manufacturing, processing, packing or holding food are not designed and of such material and workmanship as to be adequately cleanable, and are not adequately maintained to protect against allergen cross-contact and contamination, as required per 21 CFR § 117.40(a)(1). Specifically, on May 14, 2024:\u003C\u002Fp>\u003Cp>a. Employees were observed using wooden baskets to hold dough for sourdough bread. The wooden baskets were splintered, damaged, and repaired with metal nails.\u003C\u002Fp>\u003Cp>b. The wooden table in the baking room was observed damaged with deep grooves and encrusted food debris build-up on the top surface. Furthermore, metal nails and screws were observed protruding from its surface. An employee placed trays of dough on this table to cut the dough.\u003C\u002Fp>\u003Cp>c. A thick fabric liner was observed in use in the Oliver dough rolling equipment and both the Oliver dough rolling equipment and fabric liner were observed with encrusted food debris build-up.\u003C\u002Fp>\u003Cp>d. A rubber tire and nylon fabric straps were used to secure the Benier mixer and Kemper mixer from shaking during operation. Heavy debris and flour were observed accumulating on the tire and straps.\u003C\u002Fp>\u003Cp>We note that the above-mentioned observations are repeat observations from the California Department of Public Health inspection on April 12, 2017, and from the FDA inspection conducted June 2, 2021 through June 4, 2021.\u003C\u002Fp>\u003Cp>3. You did not clean and sanitize food-contact surfaces of equipment and utensils as frequently as necessary to protect against contamination of food and against allergen cross-contact, as required per 21 CFR § 117.35(d). Specifically:\u003C\u002Fp>\u003Cp>a. On May 23, 2024, food residue build-up was observed on your bagel-forming equipment. During production, the dough was observed making direct contact with the residue build-up on the equipment.\u003C\u002Fp>\u003Cp>b. On May 14, 2024, dark slime-like residue was observed on the interior surfaces of your ice machine. Ice from this machine was observed being used as an ingredient in your bakery products, such as the sourdough bread and the ciabatta bread.\u003C\u002Fp>\u003Cp>4. Your plant is not constructed in such a manner that floors, walls, and ceilings may be adequately cleaned and kept clean and kept in good repair, as required per 21 CFR § 117.20(b)(4). Specifically:\u003C\u002Fp>\u003Cp>a. On May 15, 2024, the ceiling inside the proofer room was damaged with metal rust observed on the exterior surface. Carts of exposed dough were observed directly beneath the ceiling in the proofer with steam circulating throughout the room while the proofer was in use.\u003C\u002Fp>\u003Cp>b. On May 15, 2024, standing water was observed on the floor in the dough production room which serves as a harborage condition for the growth of pathogenic bacteria. During production, the wheels of metal dough carts were observed being rolled through the standing water in the dough production room to the proofer and then to the baking room to be placed into the ovens for baking. Exposed RTE bakery products were held in the baking room for cooling.\u003C\u002Fp>\u003Cp>c. On May 15, 2024, dirt and debris accumulation was observed on the pitted floor in the RTE packaging area. Exposed RTE bakery products were observed being packaged for distribution to customers in this area.\u003C\u002Fp>\u003Cp>5. You did not take effective measures to exclude pests from the manufacturing, processing, packing, and holding areas to protect against the contamination of food on the premises by pests, as required per 21 CFR § 117.35(c). Specifically:\u003C\u002Fp>\u003Cp>a. On May 14, 2024, a flying insect was observed inside the ciabatta dough mixer in the dough production room, while the mixer was being used for production.\u003C\u002Fp>\u003Cp>b. On May 14, 2024, two flying insects landed on separate pieces of dough which were to be made into jalapeno cheese toasts. The pieces of dough were placed on the wooden dough table in the dough production room.\u003C\u002Fp>\u003Cp>c. On May 10, 2024, a flying insect was observed in the dough production room near the dry ingredient weighing area and the wooden dough table during production.\u003C\u002Fp>\u003Cp>d. On May 14, 2024, gaps greater than \u003Cstrong>(b)(4)\u003C\u002Fstrong> underneath the metal roll-up door of the dry-storage warehouse were observed which may serve as entry points for rodents.\u003C\u002Fp>\u003Cp>We note, the above-mentioned observations are repeat observations from the inspection conducted on June 2, 2021 through June 4, 2021.\u003C\u002Fp>\u003Cp>6. You did not maintain buildings, fixtures, and other physical facilities of your plant in a clean and sanitary condition and in repair adequate to prevent food from becoming adulterated, as required per 21 CFR 117.35(a). Specifically:\u003C\u002Fp>\u003Cp>a. On May 14, 2024, damaged and missing cove base tiles were observed along the walls in the dough production room as well as the baking room which resulted in exposed holes and cracks in the walls. Debris was observed accumulating along the wall with the missing cove base tiles, which is located adjacent to the cooling tunnel exit in the baking room. The exposed holes and cracks in the walls create an uncleanable niche environment which may serve as a harborage area for the growth of pathogenic bacteria.\u003C\u002Fp>\u003Cp>We note that the above-mentioned observation is a repeat observation from the inspection conducted on June 2, 2021 through June 4, 2021.\u003C\u002Fp>\u003Cp>b. On May 14, 2024, an accumulation of apparent flour dust was observed in the production room environment on non-operating equipment fixed to the ceiling such as hoppers. Exposed bread dough was observed being manipulated directly beneath this equipment.\u003C\u002Fp>\u003Cp>7. You did not conduct all food manufacturing, processing, packing, and holding under such conditions and controls as are necessary to minimize the potential for the growth of microorganisms and contamination of food, as required per 21 CFR § 117.80(c)(2). Specifically, on May 14, 2024 and May 15, 2024, exposed loaves of RTE bread were observed cooling inside your cooling tunnel where debris and dust accumulation were observed on the air vents in the cooling tunnel. The moving air passes through the air vents and directly onto the RTE bread.\u003C\u002Fp>\u003Cp>We note that the above-mentioned observation is a repeat observation from the California Department of Public Health inspection on April 12, 2017, and from the FDA inspection conducted on June 2, 2021 through June 4, 2021.\u003C\u002Fp>\u003Cp>8. Your plumbing was not adequately installed and maintained to properly convey sewage and liquid disposable waste from the plant, as required per 21 CFR § 117.37(b)(2). Specifically:\u003C\u002Fp>\u003Cp>a. On May 14, 2024, the sink drain was leaking which resulted in drain water leaking directly onto the floor in the production room.\u003C\u002Fp>\u003Cp>b. On May 14, 2024, the drain line for the ice machine was observed placed inside the floor drain without an air gap between the drain line and floor drain. Employees use ice from the ice machine for the production of your bakery products.\u003C\u002Fp>\u003Cp>9. You did not take reasonable measures and precautions to ensure that all persons working in direct contact with food, food-contact surfaces, and food-packaging materials conform to hygienic practices while on duty to the extent necessary to protect against contamination of food, as required by 21 CFR § 117.10(b). Specifically, on May 14, 2024, a personal leather bag and an open soda can were stored on a stainless-steel table with bags of bread in the RTE packaging area.\u003C\u002Fp>\u003Cp>We note that the above-mentioned observation is a repeat observation from the FDA inspection conducted September 27, through September 28, 2011, the inspection conducted by California Department of Public Health on April 30, 2014 through May 1, 2014, and the FDA inspections conducted June 2, 2021 through June 4, 2021.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of the violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your firm complies with all requirements of federal law, including FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Daniel Johnson, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Daniel Johnson via email at: Daniel.Johnson@fda.hhs.gov Please include reference CMS #668646 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, J.D., M.B.A&nbsp;&nbsp;\u003Cbr>Acting Director, Office of Enforcement&nbsp;&nbsp;\u003Cbr>Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Mehran Termechi\n\nRecipient Title\n\nOwner & Chief Executive Officer\n\nBreadbox Co.\n\n10603 Painter Ave\n\nSanta Fe Springs, CA 90670\n\nUnited States\n\nron.melrosebaking@gmail.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nNovember 18, 2024\nWARNING LETTER\nRe: CMS # 686647\nDear Mr. Termechi,\nThe United States Food and Drug Administration (FDA) inspected your human food manufacturing facility, located at 10603, Santa Fe Springs, CA, from May 10 through June 7, 2024. During the inspection, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food Regulations (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\nBased on FDA’s inspectional findings, we have determined that the ready-to-eat (RTE) bakery products manufactured in your facility are adulterated within the meaning section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and FDA’s regulations through links on FDA’s homepage at www.fda.gov.\nAt the conclusion of the inspection, FDA investigators issued a Form FDA 483 (FDA-483), Inspectional Observations, listing the deviations found at your facility. To date, FDA has not received a written response to the inspection. After reviewing the inspectional findings, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility.\nHazard Analysis and Risk-Based Preventive Controls Requirements (21 CFR Part 117, Subpart C)\nYou did not prepare, or have prepared, and implement a food safety plan, as required by 21 CFR § 117.126(a)(1). The preparation of the food safety plan must be overseen by one or more preventive controls qualified individuals (PCQIs), as required by 21 CFR § 117.126(a)(2). Your food safety plan must also include the following:\nI. The written hazard analysis, as required by 21 CFR § 117.130(a)(2);\nII. The written preventive controls, as required by 21 CFR § 117.135(b);\nIII. The written supply-chain program, as required by Subpart G;\nIV. The written recall plan, as required by 21 CFR § 117.139(a);\nV. The written procedures for monitoring the implementation of the preventive controls, as required by 21 CFR § 117.145(a);\nVI. The written corrective action procedures, as required by 21 CFR § 117.150(a)(1); and\nVII. The written verification procedures, as required by 21 CFR § 117.165(b).\nYour facility manufactures a variety of RTE bakery products, including but not limited to breads muffins, cookies, croissants, and bagels. However, you did not have a food safety plan with any of the required elements for any of the products manufactured by your facility. For example, you did not conduct a hazard analysis to identify and evaluate known or reasonably foreseeable hazards for each type of food manufactured, processed, packed, or held at your facility to determine whether there are any hazards requiring a preventive control (see 21 CFR § 117.130(a)). Also, you did not identify and implement preventive controls to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented and the food manufactured, processed, packed, or held by your facility will not be adulterated under section 402 of the Act or misbranded under section 403(w) of the Act (see 21 CFR § 117.135(a)(1)). Preventive controls include, as appropriate to the facility and the food, process controls, food allergen controls, sanitation controls, supply-chain controls, and a recall plan (see 21 CFR § 117.135(c)). Preventive controls are subject to preventive control management components (monitoring, verification, and corrective actions) as appropriate to ensure the effectiveness of the preventive controls, taking into account the nature of the preventive control and its role in the facility's food safety system (see 21 CFR § 117.140). You must also validate that the preventive controls are adequate to control the hazard as appropriate to the nature of the preventive control and its role in the facility’s food safety system (see 21 CFR § 117.160). Specifically:\na. You did not identify and evaluate allergens as a known or reasonably foreseeable hazard to determine whether allergens are a hazard requiring a preventive control (see 21 CFR § 117.130(b)(1)(ii)). Your facility manufactures more than 1900 bakery products that contain allergens (such as wheat, soy, milk, eggs, tree nuts (e.g., almonds) and sesame). These products containing different allergen profiles are processed on shared equipment using shared utensils on the same production day. Therefore, allergens are a known or reasonably foreseeable hazard. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify allergens as a hazard requiring a preventive control. Food allergen controls include procedures, practices, and processes employed for ensuring protection of food from allergen cross-contact (including during storage, handling, and use) and for labeling to ensure that all food allergens required to be stated are included on the label (see 21 CFR § 117.135(c)(2)).\nYou do not have controls in place for the hazard of allergen cross-contact, as evidenced by the following:\ni. On May 15, 2024, sesame seeds were observed embedded on the surfaces of breadsticks in at least two bags of Breadman Breadsticks (15 oz - finished product produced on May 14, 2024). The Breadman Breadsticks do not include sesame seeds as ingredients. Furthermore, on May 23, 2024, sesame seeds were observed embedded on the surfaces of breadsticks in at least two bags (unlabeled, bulk order, finished product) of breadsticks, where the ingredients do not include sesame seeds.\nii. On May 10, 2024, one of your production employees was observed using a mixer to make dough for Brioche (which contains wheat, egg, and unsalted 70% vegetable oil spread (soy lecithin, milk)). After the (b)(4) step, the production employee cleaned the mixer by scraping the excess dough from the interior of the mixer bowl and wiping it with a wet fabric cloth. Yellow, egg-like food residue, from the Brioche dough, remained on the interior of the mixer bowl. The same mixer bowl was then used to make dough for the Torpedo product which does not contain the soy or egg allergen ingredients.\nb. For your RTE bakery products, you did not identify and evaluate undeclared color additives as a reasonably foreseeable hazard to determine whether they are a hazard requiring a preventive control (see 21 CFR § 117.130(b)(1)(ii)). Your facility manufactures products containing the color additive FD&C Yellow #5. FD&C Yellow #5 is known to cause adverse reactions in sensitive individuals, including bronchial asthma in asthmatic individuals. Therefore, undeclared FD&C Yellow #5 is a known or reasonably foreseeable hazard. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify undeclared FD&C Yellow #5 as a hazard requiring a preventive control. Preventive controls include procedures, practices, and processes necessary to ensure that food manufactured processed, packed, or held by your facility will not be adulterated under section 402 or misbranded under section 403(w) (see 21 CFR 117.135(a)(1) and 21 CFR 117.135(c)(6)), such as during receipt of labels and during packaging\u002Flabeling operations, to ensure FD&C Yellow #5 is declared for products containing this color additive. You do not have controls in place, as evidenced by the following:\ni. On May 14, 2024, your facility manufactured Breadman Raisin Bread, which contains butter essence (FD&C Yellow #5) and egg shade liquid color (FD&C Yellow #5). However, the finished product label, which you distributed on May 15, 2024, did not declare FD&C Yellow #5 on the ingredients list. You recalled this product on May 16, 2024.\nii. On May 14, 2024, your facility manufactured Brioche, which contains butter essence (FD&C Yellow #5) and egg shade liquid color (FD&C Yellow #5) and distributed them to your bulk-order customers (i.e., restaurants, hotels, etc.). However, the Ingredient & Allergen Statement that you sent to your bulk-order customers did not declare FD&C Yellow #5. Additionally, you do not include the Ingredient & Allergen Statement with every delivery of bulk orders to customers. The customer only receives the statement with the initial bulk order. You distributed the Brioche on May 15, 2024 and later recalled it on May 16, 2024.\nc. For your RTE bakery products, you did not identify and evaluate recontamination with environmental pathogens, such as Salmonella, as a known or reasonably foreseeable hazard to determine whether it is a hazard requiring a preventive control, to comply with 21 CFR § 117.130(c)(1)(ii). Your facility manufactures RTE bakery products which are exposed to the environment after they exit the oven, such as while they are cooled prior to packaging. The packaged food does not receive any further lethal treatment or otherwise include a control measure (such as a formulation lethal to the pathogen) that would significantly minimize the pathogen. Therefore, recontamination with environmental pathogens is a known or reasonably foreseeable hazard. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify contamination with environmental pathogens as a hazard requiring a preventive control. Sanitation controls include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens and biological hazards due to employee handling (see 21 CFR § 117.135(c)(3)). In addition, note that environmental monitoring is required if contamination of an RTE food with an environmental pathogen is a hazard requiring a preventive control (see 21 CFR § 117.165(a)(3)). You do not have controls in place for contamination with environmental pathogens, as evidenced by the following:\ni. On May 14, 2024 and May 15, 2024, loaves of RTE bread were observed stored directly on metal racks with heavily encrusted grease and debris build-up, to be packaged and distributed to customers. These racks were in the RTE packaging area.\nii. On May 23, 2024, loaves of RTE whole wheat bread and RTE squaw bread were observed cooling directly on the same dirty metal racks in the baking room.\niii. On May 14, 2024, a production employee was observed removing loaves of RTE squaw bread from metal pans and placing them on a metal rack in the baking room using a pair of soiled fabric mittens. The soiled fabric mittens touched the loaves of RTE squaw bread. These same mittens were also used to handle oven doors and metal carts after baking. Additionally, on May 23, 2024, another production employee was observed removing loaves of RTE wholewheat bread from metal pans and placing them on a metal rack in the baking room using a pair of soiled fabric mittens. The soiled fabric mittens touched the loaves of RTE whole wheat bread.\niv. Your facility does not have an environmental monitoring program to monitor for environmental pathogens.\nd. You did not identify and evaluate mycotoxins as a known or reasonably foreseeable hazard to determine whether they require a preventive control (see 21 CFR § 117.130(b)(1)(ii)). Your facility manufactures RTE bakery products that contain wheat flour and tree nuts (e.g., almonds). These ingredients have been associated with mycotoxins. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify mycotoxins as a hazard requiring a preventive control in these ingredients. Further, a facility that identifies raw materials and other ingredients that require a supply-chain-applied control, such as mycotoxins, must establish and implement a risk-based supply-chain program for those raw materials and ingredients (see 21 CFR § 117.405(a)(1)). The supply-chain program must include using approved suppliers and conducting supplier verification activities (see 21 CFR § 117.410). You do not have this program in place.\ne. For your RTE bakery products, you did not establish a written recall plan. Your RTE bakery products have multiple known or reasonably foreseeable hazards requiring preventive controls (see 21 CFR § 117.139(a). On May 16, 2024 your facility initiated a recall of your Breadman Raisin Bread, Jalapeno Cheese Bagels and Breadman Brioche products due to the lack of proper allergen declarations and the food coloring ingredient FD&C Yellow #5 on finished product labeling.\nCurrent Good Manufacturing Practices Requirements (21 CFR Part 117, Subpart B)\n2. Your equipment and utensils used in manufacturing, processing, packing or holding food are not designed and of such material and workmanship as to be adequately cleanable, and are not adequately maintained to protect against allergen cross-contact and contamination, as required per 21 CFR § 117.40(a)(1). Specifically, on May 14, 2024:\na. Employees were observed using wooden baskets to hold dough for sourdough bread. The wooden baskets were splintered, damaged, and repaired with metal nails.\nb. The wooden table in the baking room was observed damaged with deep grooves and encrusted food debris build-up on the top surface. Furthermore, metal nails and screws were observed protruding from its surface. An employee placed trays of dough on this table to cut the dough.\nc. A thick fabric liner was observed in use in the Oliver dough rolling equipment and both the Oliver dough rolling equipment and fabric liner were observed with encrusted food debris build-up.\nd. A rubber tire and nylon fabric straps were used to secure the Benier mixer and Kemper mixer from shaking during operation. Heavy debris and flour were observed accumulating on the tire and straps.\nWe note that the above-mentioned observations are repeat observations from the California Department of Public Health inspection on April 12, 2017, and from the FDA inspection conducted June 2, 2021 through June 4, 2021.\n3. You did not clean and sanitize food-contact surfaces of equipment and utensils as frequently as necessary to protect against contamination of food and against allergen cross-contact, as required per 21 CFR § 117.35(d). Specifically:\na. On May 23, 2024, food residue build-up was observed on your bagel-forming equipment. During production, the dough was observed making direct contact with the residue build-up on the equipment.\nb. On May 14, 2024, dark slime-like residue was observed on the interior surfaces of your ice machine. Ice from this machine was observed being used as an ingredient in your bakery products, such as the sourdough bread and the ciabatta bread.\n4. Your plant is not constructed in such a manner that floors, walls, and ceilings may be adequately cleaned and kept clean and kept in good repair, as required per 21 CFR § 117.20(b)(4). Specifically:\na. On May 15, 2024, the ceiling inside the proofer room was damaged with metal rust observed on the exterior surface. Carts of exposed dough were observed directly beneath the ceiling in the proofer with steam circulating throughout the room while the proofer was in use.\nb. On May 15, 2024, standing water was observed on the floor in the dough production room which serves as a harborage condition for the growth of pathogenic bacteria. During production, the wheels of metal dough carts were observed being rolled through the standing water in the dough production room to the proofer and then to the baking room to be placed into the ovens for baking. Exposed RTE bakery products were held in the baking room for cooling.\nc. On May 15, 2024, dirt and debris accumulation was observed on the pitted floor in the RTE packaging area. Exposed RTE bakery products were observed being packaged for distribution to customers in this area.\n5. You did not take effective measures to exclude pests from the manufacturing, processing, packing, and holding areas to protect against the contamination of food on the premises by pests, as required per 21 CFR § 117.35(c). Specifically:\na. On May 14, 2024, a flying insect was observed inside the ciabatta dough mixer in the dough production room, while the mixer was being used for production.\nb. On May 14, 2024, two flying insects landed on separate pieces of dough which were to be made into jalapeno cheese toasts. The pieces of dough were placed on the wooden dough table in the dough production room.\nc. On May 10, 2024, a flying insect was observed in the dough production room near the dry ingredient weighing area and the wooden dough table during production.\nd. On May 14, 2024, gaps greater than (b)(4) underneath the metal roll-up door of the dry-storage warehouse were observed which may serve as entry points for rodents.\nWe note, the above-mentioned observations are repeat observations from the inspection conducted on June 2, 2021 through June 4, 2021.\n6. You did not maintain buildings, fixtures, and other physical facilities of your plant in a clean and sanitary condition and in repair adequate to prevent food from becoming adulterated, as required per 21 CFR 117.35(a). Specifically:\na. On May 14, 2024, damaged and missing cove base tiles were observed along the walls in the dough production room as well as the baking room which resulted in exposed holes and cracks in the walls. Debris was observed accumulating along the wall with the missing cove base tiles, which is located adjacent to the cooling tunnel exit in the baking room. The exposed holes and cracks in the walls create an uncleanable niche environment which may serve as a harborage area for the growth of pathogenic bacteria.\nWe note that the above-mentioned observation is a repeat observation from the inspection conducted on June 2, 2021 through June 4, 2021.\nb. On May 14, 2024, an accumulation of apparent flour dust was observed in the production room environment on non-operating equipment fixed to the ceiling such as hoppers. Exposed bread dough was observed being manipulated directly beneath this equipment.\n7. You did not conduct all food manufacturing, processing, packing, and holding under such conditions and controls as are necessary to minimize the potential for the growth of microorganisms and contamination of food, as required per 21 CFR § 117.80(c)(2). Specifically, on May 14, 2024 and May 15, 2024, exposed loaves of RTE bread were observed cooling inside your cooling tunnel where debris and dust accumulation were observed on the air vents in the cooling tunnel. The moving air passes through the air vents and directly onto the RTE bread.\nWe note that the above-mentioned observation is a repeat observation from the California Department of Public Health inspection on April 12, 2017, and from the FDA inspection conducted on June 2, 2021 through June 4, 2021.\n8. Your plumbing was not adequately installed and maintained to properly convey sewage and liquid disposable waste from the plant, as required per 21 CFR § 117.37(b)(2). Specifically:\na. On May 14, 2024, the sink drain was leaking which resulted in drain water leaking directly onto the floor in the production room.\nb. On May 14, 2024, the drain line for the ice machine was observed placed inside the floor drain without an air gap between the drain line and floor drain. Employees use ice from the ice machine for the production of your bakery products.\n9. You did not take reasonable measures and precautions to ensure that all persons working in direct contact with food, food-contact surfaces, and food-packaging materials conform to hygienic practices while on duty to the extent necessary to protect against contamination of food, as required by 21 CFR § 117.10(b). Specifically, on May 14, 2024, a personal leather bag and an open soda can were stored on a stainless-steel table with bags of bread in the RTE packaging area.\nWe note that the above-mentioned observation is a repeat observation from the FDA inspection conducted September 27, through September 28, 2011, the inspection conducted by California Department of Public Health on April 30, 2014 through May 1, 2014, and the FDA inspections conducted June 2, 2021 through June 4, 2021.\nThis letter is not intended to be an all-inclusive list of the violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your firm complies with all requirements of federal law, including FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\nPlease notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nPlease send your reply to the Food and Drug Administration, Attention: Daniel Johnson, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Daniel Johnson via email at: Daniel.Johnson@fda.hhs.gov Please include reference CMS #668646 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, J.D., M.B.A\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Breadbox Co.","breadbox-co-686647-11182024","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbreadbox-co-686647-11182024","2026-10-26T08:08:08.636998+00:00","Warning Letter","Issued","2025-05-20","686647","Food & Beverages","Mr. Mehran Termechi","2026-08-19T16:45:25.149+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2024-11-18",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":46,"medical_device_id":19,"response_letter_date":19},2091,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2023-05-25T13:20:00Z\">05\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-05-25T04:00:00Z\">05\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbreeze-smoke-llc-655821-05252023\">Breeze Smoke, LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mark Faraj and Steven Haddad\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Breeze Smoke, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4654 Lilly Ct.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>West Bloomfield\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48323\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@breezesmoke.com\"> info@breezesmoke.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 25, 2023\u003Cbr>\n\u003Cbr>\n\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mark Faraj and Steven Haddad:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.breezesmoke.com, and additional information, and determined that electronic nicotine delivery system (ENDS) products listed there are received and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)), and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.breezesmoke.com, and additional information, revealed that Breeze Smoke, LLC receives and delivers ENDS products without a marketing authorization order. Specifically, Breeze Smoke, LLC receives the products listed below from a foreign manufacturer and distributes those products in the United States to some or all of the retailers listed on https:\u002F\u002Fwww.breezesmoke.com. Breeze Smoke, LLC owns and operates the website https:\u002F\u002Fwww.breezesmoke.com, which lists the products below for sale, identifies retailers in the “Authorized Stores” tab of https:\u002F\u002Fwww.breezesmoke.com that sell those products, and directs consumers to those retailers. The following ENDS products offered for sale or distribution within the United States on https:\u002F\u002Fwww.smokersworldhw.com that lack a marketing authorization are Breeze Pro Disposable Vape – Candy Cane and Breeze Pro Disposable Vape - Candy Hearts.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm receives and delivers new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, and promptly take any necessary actions to bring the tobacco products into compliance with the FD&amp;C Act. It is your responsibility to ensure that these tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory or legal action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2301912, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\n\u003Cstrong>VIA USPS, UPS, and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Breeze Smoke, LLC\u003Cbr>\nAttn: Mark Faraj and Steven Haddad\u003Cbr>\n450 W. Fourth St.\u003Cbr>\nRoyal Oak, MI 48067\u003C\u002Fp>\n\n\u003Cp>Breeze Smoke\u003Cbr>\nAttn: Mark Faraj and Steven Haddad\u003Cbr>\n26056 Van Dyke Ave.\u003Cbr>\nWarren, MI 48015\u003C\u002Fp>\n\n\u003Cp>Breeze Smoke LLC\u003Cbr>\nAttn: Mark Faraj and Steven Haddad\u003Cbr>\n1471 E Nine Mile Rd., Unit 200\u003Cbr>\nHazel Park, MI 48030\u003C\u002Fp>\n\n\u003Cp>Breeze Smoke LLC\u003Cbr>\n23999 West 10 Mile Road Ste 200\u003Cbr>\nSouthfield, MI 48033\u003C\u002Fp>\n\n\u003Cp>Dongguan Shikai Technology Co., Ltd.\u003Cbr>\nAttn: Ningle Zhong\u003Cbr>\n\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Contract In-House Counsel and Consultants, LLC (d\u002Fb\u002Fa FDA Atty)\u003Cbr>\nAttn: Marc C. Sanchez\u003Cbr>\n1717 Pennsylvania Ave. NW, Suite 1025\u003Cbr>\nWashington, DC 20006\u003Cbr>\nmsanchez@fdaatty.com\u003C\u002Fp>\n\n\u003Cp>Contract In-House Counsel and Consultants, LLC (d\u002Fb\u002Fa FDA Atty)\u003Cbr>\nAttn: Marc C. Sanchez\u003Cbr>\n53516 Bickett\u003Cbr>\nChapel Hill, NC 27517\u003C\u002Fp>\n\n\u003Cp>Smokers World\u003Cbr>\n2125 Stirling Road\u003Cbr>\nFort Lauderdale, FL 33312\u003Cbr>\nINFO@smokersworldhw.com\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>Wix.com Inc\u003Cbr>\nabuse@wix.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nMark Faraj and Steven Haddad\n\nBreeze Smoke, LLC\n\n4654 Lilly Ct.\n\nWest Bloomfield, MI 48323\n\nUnited States\n\ninfo@breezesmoke.com\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMay 25, 2023\n\nWARNING LETTER\n\nDear Mark Faraj and Steven Haddad:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.breezesmoke.com, and additional information, and determined that electronic nicotine delivery system (ENDS) products listed there are received and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)), and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.breezesmoke.com, and additional information, revealed that Breeze Smoke, LLC receives and delivers ENDS products without a marketing authorization order. Specifically, Breeze Smoke, LLC receives the products listed below from a foreign manufacturer and distributes those products in the United States to some or all of the retailers listed on https:\u002F\u002Fwww.breezesmoke.com. Breeze Smoke, LLC owns and operates the website https:\u002F\u002Fwww.breezesmoke.com, which lists the products below for sale, identifies retailers in the “Authorized Stores” tab of https:\u002F\u002Fwww.breezesmoke.com that sell those products, and directs consumers to those retailers. The following ENDS products offered for sale or distribution within the United States on https:\u002F\u002Fwww.smokersworldhw.com that lack a marketing authorization are Breeze Pro Disposable Vape – Candy Cane and Breeze Pro Disposable Vape - Candy Hearts.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, these products are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has determined that your firm receives and delivers new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, and promptly take any necessary actions to bring the tobacco products into compliance with the FD&C Act. It is your responsibility to ensure that these tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory or legal action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2301912, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA USPS, UPS, and Electronic Mail\n\ncc:\n\nBreeze Smoke, LLC\n\nAttn: Mark Faraj and Steven Haddad\n\n450 W. Fourth St.\n\nRoyal Oak, MI 48067\n\nBreeze Smoke\n\nAttn: Mark Faraj and Steven Haddad\n\n26056 Van Dyke Ave.\n\nWarren, MI 48015\n\nBreeze Smoke LLC\n\nAttn: Mark Faraj and Steven Haddad\n\n1471 E Nine Mile Rd., Unit 200\n\nHazel Park, MI 48030\n\nBreeze Smoke LLC\n\n23999 West 10 Mile Road Ste 200\n\nSouthfield, MI 48033\n\nDongguan Shikai Technology Co., Ltd.\n\nAttn: Ningle Zhong\n\n(b)(6)\n\nContract In-House Counsel and Consultants, LLC (d\u002Fb\u002Fa FDA Atty)\n\nAttn: Marc C. Sanchez\n\n1717 Pennsylvania Ave. NW, Suite 1025\n\nWashington, DC 20006\n\nmsanchez@fdaatty.com\n\nContract In-House Counsel and Consultants, LLC (d\u002Fb\u002Fa FDA Atty)\n\nAttn: Marc C. Sanchez\n\n53516 Bickett\n\nChapel Hill, NC 27517\n\nSmokers World\n\n2125 Stirling Road\n\nFort Lauderdale, FL 33312\n\nINFO@smokersworldhw.com\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nWix.com Inc\n\nabuse@wix.com","Breeze Smoke, LLC","breeze-smoke-llc-655821-05252023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbreeze-smoke-llc-655821-05252023","2026-10-26T08:08:08.72598+00:00","2023-05-25","655821","Tobacco","Mark Faraj and Steven Haddad","2026-08-20T01:06:04.038+00:00","VIA UPS and Electronic Mail",{"id":53,"raw":54,"subject":38,"body_html":58,"body_text":59,"firm_name":60,"letter_id":61,"created_at":43,"fei_number":19,"letter_url":62,"updated_at":63,"action_type":22,"case_status":23,"posted_date":64,"marcs_cms_no":65,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":66,"body_fetched_at":67,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":64,"medical_device_id":19,"response_letter_date":19},2162,[55,56,57,37,38,13,13,13],"\u003Ctime datetime=\"2023-03-15T19:00:00Z\">03\u002F15\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-15T04:00:00Z\">03\u002F15\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbreezesmokes-llc-654166-03152023\">Breezesmokes LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Donald J. Dameron &amp; Mrs. Rhonda L. Dameron\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owners\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Breezesmokes LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1605 North Valley Mills Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Waco\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76710\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:breezesmokes@yahoo.com\"> breezesmokes@yahoo.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 15, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. &amp; Mrs. Dameron:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Breezesmokes LLC manufactures, imports, and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured, imported, and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, import, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Breezesmokes Cinnamon 11mg 30ml and Breezesmokes USA Tobacco 3mg 50ml.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2300812, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nMr. Donald J. Dameron & Mrs. Rhonda L. Dameron\n\nRecipient Title\n\nOwners\n\nBreezesmokes LLC\n\n1605 North Valley Mills Drive\n\nWaco, TX 76710\n\nUnited States\n\nbreezesmokes@yahoo.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMarch 15, 2023\n\nWARNING LETTER\n\nDear Mr. & Mrs. Dameron:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Breezesmokes LLC manufactures, imports, and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured, imported, and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, import, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Breezesmokes Cinnamon 11mg 30ml and Breezesmokes USA Tobacco 3mg 50ml.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nAll new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2300812, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Breezesmokes LLC","breezesmokes-llc-654166-03152023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbreezesmokes-llc-654166-03152023","2026-10-26T08:08:08.823566+00:00","2023-03-15","654166","Mr. Donald J. Dameron & Mrs. Rhonda L. Dameron","2026-08-20T01:11:52.971+00:00",{"id":69,"raw":70,"subject":38,"body_html":74,"body_text":75,"firm_name":76,"letter_id":77,"created_at":78,"fei_number":19,"letter_url":79,"updated_at":80,"action_type":22,"case_status":23,"posted_date":81,"marcs_cms_no":82,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":83,"body_fetched_at":84,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":81,"medical_device_id":19,"response_letter_date":19},2529,[71,72,73,37,38,13,13,13],"\u003Ctime datetime=\"2022-08-04T19:00:00Z\">08\u002F04\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-04T04:00:00Z\">08\u002F04\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrew-city-juice-llc-638937-08042022\">Brew City Juice, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Philip M. Allen, Jr.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Brew City Juice, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2018 South 1st Street, Suite 333\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Milwaukee\u003C\u002Fspan>, \u003Cspan>WI\u003C\u002Fspan> \u003Cspan>53207-1102\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:pj@brewcityjuice.com\"> pj@brewcityjuice.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 4, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Allen:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Brew City Juice, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: No Name Blue Moon 3mg 60ml, and Brew City Blue Razz 3mg 60ml.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 140 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200594, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nPhilip M. Allen, Jr.\n\nRecipient Title\n\nOwner\n\nBrew City Juice, LLC\n\n2018 South 1st Street, Suite 333\n\nMilwaukee, WI 53207-1102\n\nUnited States\n\npj@brewcityjuice.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nAugust 4, 2022\n\nWARNING LETTER\n\nDear Mr. Allen:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Brew City Juice, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: No Name Blue Moon 3mg 60ml, and Brew City Blue Razz 3mg 60ml.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 140 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200594, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Brew City Juice, LLC","brew-city-juice-llc-638937-08042022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrew-city-juice-llc-638937-08042022","2026-10-26T08:08:08.898689+00:00","2022-08-04","638937","Philip M. Allen, Jr.","2026-08-20T01:41:38.051+00:00",{"id":86,"raw":87,"subject":38,"body_html":90,"body_text":91,"firm_name":92,"letter_id":93,"created_at":43,"fei_number":19,"letter_url":94,"updated_at":95,"action_type":22,"case_status":23,"posted_date":96,"marcs_cms_no":19,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":83,"body_fetched_at":97,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":81,"medical_device_id":19,"response_letter_date":19},2476,[88,72,89,37,38,13,13,13],"\u003Ctime datetime=\"2022-09-06T13:20:00Z\">09\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrew-city-juice-llc-638937-08042022-0\">Brew City Juice LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Philip M. Allen, Jr.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Brew City Juice LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2018 South 1st Street, Suite 333\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Milwaukee\u003C\u002Fspan>, \u003Cspan>WI\u003C\u002Fspan> \u003Cspan>53207-1102\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:pj@brewcityjuice.com\"> pj@brewcityjuice.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 4, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Allen:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Brew City Juice, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: No Name Blue Moon 3mg 60ml, and\u003Cbr>\nBrew City Blue Razz 3mg 60ml.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 140 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200594, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nPhilip M. Allen, Jr.\n\nRecipient Title\n\nOwner\n\nBrew City Juice LLC\n\n2018 South 1st Street, Suite 333\n\nMilwaukee, WI 53207-1102\n\nUnited States\n\npj@brewcityjuice.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nAugust 4, 2022\n\nWARNING LETTER\n\nDear Mr. Allen:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Brew City Juice, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: No Name Blue Moon 3mg 60ml, and\n\nBrew City Blue Razz 3mg 60ml.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 140 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200594, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Brew City Juice LLC","brew-city-juice-llc-638937-08042022-0","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrew-city-juice-llc-638937-08042022-0","2026-10-26T08:08:08.948745+00:00","2022-09-06","2026-08-20T01:36:19.183+00:00",{"id":99,"raw":100,"subject":38,"body_html":104,"body_text":105,"firm_name":106,"letter_id":107,"created_at":108,"fei_number":19,"letter_url":109,"updated_at":110,"action_type":22,"case_status":23,"posted_date":111,"marcs_cms_no":112,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":113,"body_fetched_at":114,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":115,"medical_device_id":19,"response_letter_date":19},3293,[101,102,103,37,38,13,13,13],"\u003Ctime datetime=\"2021-06-29T13:20:00Z\">06\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-25T04:00:00Z\">06\u002F25\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwyo-witches-brew-llc-615597-06252021\">Wyo Witches Brew LLC \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Holly Stone\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Wyo Witches Brew LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>927 Main Street, Suite 500\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Evanston\u003C\u002Fspan>, \u003Cspan>WY\u003C\u002Fspan> \u003Cspan>82930\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:wyowitchesbrew@gmail.com\"> wyowitchesbrew@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 25, 2021\u003Cbr>\n\u003Cbr>\n\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Holly Stone:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwyowitchesbrew.company and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwyowitchesbrew.company revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Wyo Witches Brew Warlock and Wyo Witches Brew Strawberry Ice Cream.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 9,700 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2101613, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>VIA UPS and Electronic Mail\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Wyo Witches Brew, LLC Attn: Holly Stone\u003Cbr>\n140 Del Rio Drive\u003Cbr>\nEvanston, WY 82930\u003C\u002Fp>\n\n\u003Cp>Network Solutions, LLC\u003Cbr>\nabuse@web.com\u003C\u002Fp>\n\n\u003Cp>Wix.com, Inc.\u003Cbr>\nabuse@wix.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nHolly Stone\n\nWyo Witches Brew LLC\n\n927 Main Street, Suite 500\n\nEvanston, WY 82930\n\nUnited States\n\nwyowitchesbrew@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJune 25, 2021\n\nWARNING LETTER\n\nDear Holly Stone:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwyowitchesbrew.company and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwyowitchesbrew.company revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Wyo Witches Brew Warlock and Wyo Witches Brew Strawberry Ice Cream.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 9,700 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101613, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nWyo Witches Brew, LLC Attn: Holly Stone\n\n140 Del Rio Drive\n\nEvanston, WY 82930\n\nNetwork Solutions, LLC\n\nabuse@web.com\n\nWix.com, Inc.\n\nabuse@wix.com","Wyo Witches Brew LLC","wyo-witches-brew-llc-615597-06252021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwyo-witches-brew-llc-615597-06252021","2026-10-26T08:10:34.628679+00:00","2021-06-29","615597","Holly Stone","2026-08-20T03:03:13.897+00:00","2021-06-25",{"id":117,"raw":118,"subject":123,"body_html":124,"body_text":125,"firm_name":126,"letter_id":127,"created_at":128,"fei_number":19,"letter_url":129,"updated_at":130,"action_type":22,"case_status":23,"posted_date":131,"marcs_cms_no":132,"product_type":26,"closeout_date":19,"issuing_office":133,"recipient_name":134,"body_fetched_at":135,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":136,"medical_device_id":19,"response_letter_date":19},1459,[119,120,121,122,123,13,13,13],"\u003Ctime datetime=\"2024-05-14T13:20:00Z\">05\u002F14\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-25T04:00:00Z\">04\u002F25\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalifornia-bread-co-674283-04252024\">California Bread Co.\u003C\u002Fa>"," Division of Human and Animal Food Operations West V","Food Labeling\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Steve S. Shorees, CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Rene A. Garcia, President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>California Bread Co.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>681 Anita St, Ste 106\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chula Vista\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91911\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 25, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Shorees and Mr. Garcia:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your manufacturing facility, located at 681 Anita St, Ste 106, Chula Vista, CA 91911, from October 24 through November 28, 2023. The inspection revealed significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). Based on FDA’s inspectional findings, we have determined that you did not follow the requirements of the CGMP &amp; PC rule. The failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP &amp; PC rule through links on FDA's website at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>In addition, your Egg Bread product is also adulterated under section 402(c) of the Act [21 U.S.C. § 342(c)] because it contains a color additive which is unsafe within the meaning of section 721(a) of the Act [21 U.S.C. § 379e(a)]. Further, we found significant violations of the labeling regulations for foods, 21 CFR Part 101. These violations cause your products described below to be misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343].\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, the FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations. We received your response describing corrective actions to the FDA-483 on December 13, 2023, with additional documentation received on December 20 and 21, 2023. After reviewing the inspectional findings and your responses, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility. Your responses are addressed below as necessary.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Hazard Analysis and Risk-Based Preventive Controls (21 CFR 117 Subpart C):\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. Your written allergen preventive control did not include procedures, practices, and processes employed for labeling to ensure that all food allergens required to be stated are included on the label for your RTE bread products, as required by 21 CFR 117.135(c)(2)(ii).\u003C\u002Fp>\n\n\u003Cp>Specifically, your hazard analysis for your various bread products (part of your HACCP Plan dated November 2, 2023) identified allergens as a significant hazard requiring a Critical Control Point (CCP) at the packaging\u002Flabeling step. However, your Allergens Management Program did not specifically identify the milk allergen in your sweet whey ingredient. You did not declare the milk allergen on your label for La Torta (Telera) bread products, lot # TAN NOV15, on November 2, 2023. You initiated a voluntary recall the following day covering La Torta (Telera) bread products manufactured back through October 24, 2023.\u003C\u002Fp>\n\n\u003Cp>Your December 13, 2023 response states that you are in the process of ordering new La Torta Bread printed bags, and that you are temporarily placing a corrected printed label on top of old printed bags or clear bags. Your December 21, 2023 response includes a revised process control at the “Labeling and Print bag” step which addresses allergen declaration accuracy. It also addresses application of temporary or sticker labels (i.e., ensuring that correct labels are placed on old\u002Fprinted or clear bags), but it does not appear to address use of printed bags in production (i.e., ensuring that correct preprinted bags are used while packaging finished product). Furthermore, you have not provided supporting documentation demonstrating you have implemented the finished product label check for allergen declarations. In your response to this letter, you should provide your revised written preventive control procedures and completed allergen labeling monitoring records for at least five consecutive days of production.\u003C\u002Fp>\n\n\u003Cp>2. You did not identify and evaluate all known or reasonably foreseeable hazards to determine whether there are hazards requiring a preventive control for your RTE bread products, as required by 21 CFR 117.130(a)(1).\u003C\u002Fp>\n\n\u003Cp>Specifically, your hazard analysis for your various bread products did not identify and evaluate the hazard of undeclared color additives, to determine whether it requires a preventive control. Your facility manufactures bread products (including Egg Bread) containing color additives (including FD&amp;C Yellow #5). FD&amp;C Yellow #5 is known to cause adverse reactions in sensitive individuals, including bronchial asthma in asthmatic individuals. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify undeclared FD&amp;C Yellow #5 as a hazard requiring a preventive control. Preventive controls include procedures, practices, and processes necessary to ensure that food manufactured processed, packed, or held by your facility will not be adulterated under section 402 or misbranded under section 403(w) (see 21 CFR 117.135(a)(1) and 21 CFR 117.135(c)(6)), such as during receipt of labels and during packaging\u002Flabeling operations, to ensure FD&amp;C Yellow #5 is declared for products containing this color additive.\u003C\u002Fp>\n\n\u003Cp>You did not have controls in place, as evidenced by your manufacturing and distributing Egg Bread, lot # TAN NOV15, on November 2, 2023, with labels that did not declare the presence of FD&amp;C Yellow #5.\u003Cbr>\n\u003Cbr>\nYour December 13, 2023 response states that Egg Bread bags are currently being labeled with a revised\u002Fcorrected label, placed on top of the printed bags. You are awaiting your bag supplier’s new plates to begin printing corrected new Egg Bread Bags. Your December 21, 2023 response includes a process control for undeclared sub-ingredients in Egg Bread. Your critical limit requires that egg shade containing Yellow #5 and Yellow #6 be specified in the labels or printed bags. However, your critical limit does not include ensuring that Egg Bread labels or bags are used in production while packaging the Egg Bread. Furthermore, you have not provided supporting documentation demonstrating you have implemented the finished product label check for color additive declarations. In your response to this letter, you should provide your revised written procedures for undeclared color additives and completed labeling monitoring records for at least five consecutive days of production.\u003C\u002Fp>\n\n\u003Cp>3. You did not implement your preventive controls procedures to significantly minimize or prevent contamination with the hazard of environmental pathogens in your RTE bread products, as required by 21 CFR 117.135(a)(1).\u003C\u002Fp>\n\n\u003Cp>Specifically, your hazard analysis for your various bread products, including RTE La Torta Bread (Telera Bread), identified the hazard of non-spore forming pathogens such as E. coli, Salmonella, and Listeria as requiring a preventive control at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step. Also, your written Sanitation Standard Operating Procedure (SSOP) required that you “[o]bserve equipment for missing parts or parts\u002Fsurfaces that are worn to the extent that debris will accumulate and cause product contamination. When the preventive maintenance technician is involved, he must replace or repair parts\u002Fsurfaces per request or as needed, and document what was done in the work order.” However, during production of your RTE La Torta Bread (Telera Bread), lot # TAN NOV15, on November 2, 2023, FDA investigators observed that the food-contact conveyor belt on the LeMatic slicer (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) was discolored, contained frayed edges, and had an unsmooth metal lace. Your Pre-Operational \u002F Post-Operational Daily Inspection Sheet for November 2, 2o23, found that the packaging areas were “in good order, clean &amp; sanitized.”\u003C\u002Fp>\n\n\u003Cp>Your December 13, 2023 response states that you have \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that your Quality Assurance personnel oversees monitoring for repairs and corrective actions on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis. Your corrective actions will be verified during the next FDA inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Color Additive Labeling\u003C\u002Fstrong>\u003Cbr>\nYour Egg Bread products are adulterated within the meaning of section 402(c) of the Act [21 U.S.C. § 342(c)] because the products bear or contain a color additive which is unsafe within the meaning of section 721(a) of the Act [21 U.S.C. § 379e(a)]. Section 721(a) deems a color additive to be unsafe unless its use is in conformity with the color additive listing regulation. Specifically, the listing regulation for FD&amp;C Yellow No. 5 requires that this certified color additive be listed as “FD&amp;C Yellow No. 5” in the ingredient list on the labels of foods for human use that contain FD&amp;C Yellow No. 5 [21 CFR 74.705(d)(2)]. Your Egg Bread product is manufactured with \u003Cstrong>(b)(4)\u003C\u002Fstrong> Egg Shade which contains FD&amp;C Yellow No. 5; however, the label for this product fails to declare FD&amp;C Yellow No. 5 in the ingredient statement.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranding\u003C\u002Fstrong>\u003Cbr>\n1. Your La Torta Bread (72 oz.), Telera (32 oz. and 61 oz.), and Egg Bread (24 oz. and 32 oz.) products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that it is fabricated from two or more ingredients and each ingredient is not declared on the label and the labels fail to declare the ingredients by their common or usual names, as required by 21 CFR 101.4. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. The La Torta Bread product label does not list the ingredients in descending order of predominance by weight, as required by 21 CFR 101.4(a)(1). The label lists yeast after gluten, but your product formula indicates the amount of yeast used to manufacture the product is higher than the amount of gluten.\u003Cbr>\nb. The La Torta Bread and Egg Bread ingredient lists declare the terms “Tempest,” “Viva Fresco Prime 150,” “softener,” “Lovibond red color,” and “Lovibond yellow color,” and the Telera label includes the terms “Tempest” and “softener,” none of which are appropriate common or usual names of ingredients, as required by 21 CFR 101.4(a). The Lovibond is a scale of color measurement and not an ingredient. “Tempest” and “Viva Fresco Prime 150” appear to be brand names. “Softener” appears to be a description of the function of an ingredient; however, it is not a term provided for in 21 CFR 101.4.\u003Cbr>\nc. The term “fresh” on the La Torta Bread, Telera, and Egg Bread ingredient lists is not part of the common or usual name of yeast.\u003Cbr>\nd. The term “Egg Shade Powder” on the Egg Bread product label is not an appropriate declaration for colors.\u003Cbr>\ne. The Telera label declares “Salad Oil (soybean oil)” which is not declared in accordance with 21 CFR 101.4(b)(14).\u003Cbr>\nf. The Egg Bread product label lists “Egg Shade Powder (Yellow#5, Yellow#6);” this is not an appropriate declaration for colors.\u003C\u002Fp>\n\n\u003Cp>2. Your La Torta Bread (72 oz.), Telera (32 oz. and 61 oz.), and Egg Bread (24 oz. and 32 oz.) products are misbranded within the meaning of section 403(q) of the Act [21 U.S.C. 343(q)] in that the nutrition information (e.g., Nutrition Facts label) does not comply with the requirements in 21 CFR 101.9. For example:\u003C\u002Fp>\n\n\u003Cp>a. The nutrients, including the vitamins and minerals, declared in the Nutrition Facts label (NFL) are not in accordance with 21 CFR 101.9(c), and the format is not in accordance with 21 CFR 101.9(d).\u003Cbr>\nb. Your pre-printed bread bags for both La Torta Bread and Egg Bread bear the nutrient content claims, “Cholesterol Free” and “No Trans Fat,” but the NFL does not include declarations for polyunsaturated fat and monounsaturated fat as required by 21 CFR 101.9(c)(2)(iii). Under 21 CFR 101.9(c)(2)(ii) and (iv), mono- and polyunsaturated fats must be declared on the NFL if claims about fatty acids or cholesterol are made on the label or in the labeling of a food other than one that meets the criteria in 21 CFR 101.62(b)(1) for a “fat free” claim.\u003Cbr>\nc. The Egg Bread label does not declare Added Sugars in accordance with 21 CFR 101.9(c)(6) in that the label declares zero grams of added sugar, but light brown sugar is listed as the third most prominent ingredient.\u003Cbr>\nd. The La Torta Bread product label contains a footnote not provided for under 21 CFR 101.9(d)(9).\u003C\u002Fp>\n\n\u003Cp>3. Your Telera (32 oz. and 61 oz.) product is misbranded within the meaning of section 403(i)(1) of the Act [21 U.S.C. 343(i)(1)] in that the product label does not contain an appropriate statement of identity, as required in 21 CFR 101.3(b). “Telera” is a Spanish term and is not an appropriate common or usual name.\u003Cbr>\n\u003Cbr>\n4. Your La Torta Bread (72 oz.) and Telera (32 oz. and 61 oz.) products are misbranded within the meaning of section 403(f) of the Act [21 U.S.C. 343(f)] because the product labels provide information in two languages but do not repeat all required information in both languages. For example, both labels include foreign terms in the statement of identities; however, all required labeling is not also provided in the foreign language, as required by 21 CFR 101.15(c)(2).\u003C\u002Fp>\n\n\u003Cp>5. Your Egg Bread (24 oz. and 32 oz.) product is misbranded within the meaning of section 403(g) of the Act [21 U.S.C. 343(g)]. The product appears to be represented as a food for which a definition and standard of identity have been prescribed by regulations as provided by section 401, but it does not appear to conform to such definition and standard in accordance with 21 CFR 136.110. Specifically, egg bread is subject to the standard of identity in 21 CFR 136.110 which requires, among other things, that the food shall contain not less than 2.56 percent of whole egg solids [21 CFR 136.110(e)(2)]; however, this product fails to contain egg as an ingredient.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive list of the violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal or regulatory action, including without limitation, seizure or injunction.\u003C\u002Fp>\n\n\u003Cp>In addition to the above violations, we offer the following comments:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The review of your firm’s product labels was limited to the products and sizes listed above. However, you should conduct a review of all your product labels and make appropriate corrections across all products and product sizes.\u003C\u002Fli>\n\t\u003Cli>We note that the Telera, La Torta Bread, and Egg Bread products declare “soybean” in a “Food Allergy Contains” statement. If this statement is meant to be a “Contains” statement as provided for under section 403(w) of the Act, then the words “Food Allergy” need to be removed. Additionally, if the ingredient “soybean oil” is the only soy ingredient, and if it is highly refined soybean oil, then is it is not a major food allergen and it should not be declared in the “Contains” statement. You should review your product formulations to ensure all major food allergens and ingredients are declared appropriately.\u003C\u002Fli>\n\t\u003Cli>As noted above, all the product labels bear the claim “No Trans Fat.” However, FDA has not authorized any nutrient content claims for trans fat, such as “trans fat free,” “no trans fat,” or “zero trans fat.” Under section 403(r)(1)(A) of the Act, a nutrient content claim in food labeling must be made in accordance with a regulation authorizing the use of the claim for the food bearing such a claim not to be misbranded. Although FDA has not defined the term “No Trans Fat” by regulation, we announced in the Federal Register dated July 11, 2003 (68 FR 41507 at 41509) that we would likely consider exercising enforcement discretion for a trans-fat nutrient content claim that is demonstrably true, balanced, adequately substantiated, and not misleading. We point out that, 21 CFR 101.13(i)(3) permits statements about the amount or percentage of a nutrient if the statement does not in any way implicitly characterize the level of the nutrient in the food, and it is not false or misleading in any respect (e.g., \"0 g trans fat”).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\n1201 Harbor Bay Pkwy\u003Cbr>\nAlameda, CA 94502\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number \u003Cstrong>674283\u003C\u002Fstrong> when replying.\u003C\u002Fp>\n\n\u003Cp>If you would prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification Number in the title of the e-mail message.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at Elodie.Tong-Lin@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations – West Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Steve S. Shorees, CEO\n\nRecipient Title\n\nMr. Rene A. Garcia, President\n\nCalifornia Bread Co.\n\n681 Anita St, Ste 106\n\nChula Vista, CA 91911\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West V\n\nUnited States\n\nWARNING LETTER\n\nApril 25, 2024\n\nDear Mr. Shorees and Mr. Garcia:\n\nThe United States Food and Drug Administration (FDA) inspected your manufacturing facility, located at 681 Anita St, Ste 106, Chula Vista, CA 91911, from October 24 through November 28, 2023. The inspection revealed significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). Based on FDA’s inspectional findings, we have determined that you did not follow the requirements of the CGMP & PC rule. The failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP & PC rule through links on FDA's website at http:\u002F\u002Fwww.fda.gov.\n\nIn addition, your Egg Bread product is also adulterated under section 402(c) of the Act [21 U.S.C. § 342(c)] because it contains a color additive which is unsafe within the meaning of section 721(a) of the Act [21 U.S.C. § 379e(a)]. Further, we found significant violations of the labeling regulations for foods, 21 CFR Part 101. These violations cause your products described below to be misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343].\n\nAt the conclusion of the inspection, the FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations. We received your response describing corrective actions to the FDA-483 on December 13, 2023, with additional documentation received on December 20 and 21, 2023. After reviewing the inspectional findings and your responses, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility. Your responses are addressed below as necessary.\n\nHazard Analysis and Risk-Based Preventive Controls (21 CFR 117 Subpart C):\n\n1. Your written allergen preventive control did not include procedures, practices, and processes employed for labeling to ensure that all food allergens required to be stated are included on the label for your RTE bread products, as required by 21 CFR 117.135(c)(2)(ii).\n\nSpecifically, your hazard analysis for your various bread products (part of your HACCP Plan dated November 2, 2023) identified allergens as a significant hazard requiring a Critical Control Point (CCP) at the packaging\u002Flabeling step. However, your Allergens Management Program did not specifically identify the milk allergen in your sweet whey ingredient. You did not declare the milk allergen on your label for La Torta (Telera) bread products, lot # TAN NOV15, on November 2, 2023. You initiated a voluntary recall the following day covering La Torta (Telera) bread products manufactured back through October 24, 2023.\n\nYour December 13, 2023 response states that you are in the process of ordering new La Torta Bread printed bags, and that you are temporarily placing a corrected printed label on top of old printed bags or clear bags. Your December 21, 2023 response includes a revised process control at the “Labeling and Print bag” step which addresses allergen declaration accuracy. It also addresses application of temporary or sticker labels (i.e., ensuring that correct labels are placed on old\u002Fprinted or clear bags), but it does not appear to address use of printed bags in production (i.e., ensuring that correct preprinted bags are used while packaging finished product). Furthermore, you have not provided supporting documentation demonstrating you have implemented the finished product label check for allergen declarations. In your response to this letter, you should provide your revised written preventive control procedures and completed allergen labeling monitoring records for at least five consecutive days of production.\n\n2. You did not identify and evaluate all known or reasonably foreseeable hazards to determine whether there are hazards requiring a preventive control for your RTE bread products, as required by 21 CFR 117.130(a)(1).\n\nSpecifically, your hazard analysis for your various bread products did not identify and evaluate the hazard of undeclared color additives, to determine whether it requires a preventive control. Your facility manufactures bread products (including Egg Bread) containing color additives (including FD&C Yellow #5). FD&C Yellow #5 is known to cause adverse reactions in sensitive individuals, including bronchial asthma in asthmatic individuals. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify undeclared FD&C Yellow #5 as a hazard requiring a preventive control. Preventive controls include procedures, practices, and processes necessary to ensure that food manufactured processed, packed, or held by your facility will not be adulterated under section 402 or misbranded under section 403(w) (see 21 CFR 117.135(a)(1) and 21 CFR 117.135(c)(6)), such as during receipt of labels and during packaging\u002Flabeling operations, to ensure FD&C Yellow #5 is declared for products containing this color additive.\n\nYou did not have controls in place, as evidenced by your manufacturing and distributing Egg Bread, lot # TAN NOV15, on November 2, 2023, with labels that did not declare the presence of FD&C Yellow #5.\n\nYour December 13, 2023 response states that Egg Bread bags are currently being labeled with a revised\u002Fcorrected label, placed on top of the printed bags. You are awaiting your bag supplier’s new plates to begin printing corrected new Egg Bread Bags. Your December 21, 2023 response includes a process control for undeclared sub-ingredients in Egg Bread. Your critical limit requires that egg shade containing Yellow #5 and Yellow #6 be specified in the labels or printed bags. However, your critical limit does not include ensuring that Egg Bread labels or bags are used in production while packaging the Egg Bread. Furthermore, you have not provided supporting documentation demonstrating you have implemented the finished product label check for color additive declarations. In your response to this letter, you should provide your revised written procedures for undeclared color additives and completed labeling monitoring records for at least five consecutive days of production.\n\n3. You did not implement your preventive controls procedures to significantly minimize or prevent contamination with the hazard of environmental pathogens in your RTE bread products, as required by 21 CFR 117.135(a)(1).\n\nSpecifically, your hazard analysis for your various bread products, including RTE La Torta Bread (Telera Bread), identified the hazard of non-spore forming pathogens such as E. coli, Salmonella, and Listeria as requiring a preventive control at the “(b)(4)” step. Also, your written Sanitation Standard Operating Procedure (SSOP) required that you “[o]bserve equipment for missing parts or parts\u002Fsurfaces that are worn to the extent that debris will accumulate and cause product contamination. When the preventive maintenance technician is involved, he must replace or repair parts\u002Fsurfaces per request or as needed, and document what was done in the work order.” However, during production of your RTE La Torta Bread (Telera Bread), lot # TAN NOV15, on November 2, 2023, FDA investigators observed that the food-contact conveyor belt on the LeMatic slicer ((b)(4)) was discolored, contained frayed edges, and had an unsmooth metal lace. Your Pre-Operational \u002F Post-Operational Daily Inspection Sheet for November 2, 2o23, found that the packaging areas were “in good order, clean & sanitized.”\n\nYour December 13, 2023 response states that you have (b)(4) and that your Quality Assurance personnel oversees monitoring for repairs and corrective actions on a (b)(4) basis. Your corrective actions will be verified during the next FDA inspection.\n\nColor Additive Labeling\n\nYour Egg Bread products are adulterated within the meaning of section 402(c) of the Act [21 U.S.C. § 342(c)] because the products bear or contain a color additive which is unsafe within the meaning of section 721(a) of the Act [21 U.S.C. § 379e(a)]. Section 721(a) deems a color additive to be unsafe unless its use is in conformity with the color additive listing regulation. Specifically, the listing regulation for FD&C Yellow No. 5 requires that this certified color additive be listed as “FD&C Yellow No. 5” in the ingredient list on the labels of foods for human use that contain FD&C Yellow No. 5 [21 CFR 74.705(d)(2)]. Your Egg Bread product is manufactured with (b)(4) Egg Shade which contains FD&C Yellow No. 5; however, the label for this product fails to declare FD&C Yellow No. 5 in the ingredient statement.\n\nMisbranding\n\n1. Your La Torta Bread (72 oz.), Telera (32 oz. and 61 oz.), and Egg Bread (24 oz. and 32 oz.) products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that it is fabricated from two or more ingredients and each ingredient is not declared on the label and the labels fail to declare the ingredients by their common or usual names, as required by 21 CFR 101.4. Specifically:\n\na. The La Torta Bread product label does not list the ingredients in descending order of predominance by weight, as required by 21 CFR 101.4(a)(1). The label lists yeast after gluten, but your product formula indicates the amount of yeast used to manufacture the product is higher than the amount of gluten.\n\nb. The La Torta Bread and Egg Bread ingredient lists declare the terms “Tempest,” “Viva Fresco Prime 150,” “softener,” “Lovibond red color,” and “Lovibond yellow color,” and the Telera label includes the terms “Tempest” and “softener,” none of which are appropriate common or usual names of ingredients, as required by 21 CFR 101.4(a). The Lovibond is a scale of color measurement and not an ingredient. “Tempest” and “Viva Fresco Prime 150” appear to be brand names. “Softener” appears to be a description of the function of an ingredient; however, it is not a term provided for in 21 CFR 101.4.\n\nc. The term “fresh” on the La Torta Bread, Telera, and Egg Bread ingredient lists is not part of the common or usual name of yeast.\n\nd. The term “Egg Shade Powder” on the Egg Bread product label is not an appropriate declaration for colors.\n\ne. The Telera label declares “Salad Oil (soybean oil)” which is not declared in accordance with 21 CFR 101.4(b)(14).\n\nf. The Egg Bread product label lists “Egg Shade Powder (Yellow#5, Yellow#6);” this is not an appropriate declaration for colors.\n\n2. Your La Torta Bread (72 oz.), Telera (32 oz. and 61 oz.), and Egg Bread (24 oz. and 32 oz.) products are misbranded within the meaning of section 403(q) of the Act [21 U.S.C. 343(q)] in that the nutrition information (e.g., Nutrition Facts label) does not comply with the requirements in 21 CFR 101.9. For example:\n\na. The nutrients, including the vitamins and minerals, declared in the Nutrition Facts label (NFL) are not in accordance with 21 CFR 101.9(c), and the format is not in accordance with 21 CFR 101.9(d).\n\nb. Your pre-printed bread bags for both La Torta Bread and Egg Bread bear the nutrient content claims, “Cholesterol Free” and “No Trans Fat,” but the NFL does not include declarations for polyunsaturated fat and monounsaturated fat as required by 21 CFR 101.9(c)(2)(iii). Under 21 CFR 101.9(c)(2)(ii) and (iv), mono- and polyunsaturated fats must be declared on the NFL if claims about fatty acids or cholesterol are made on the label or in the labeling of a food other than one that meets the criteria in 21 CFR 101.62(b)(1) for a “fat free” claim.\n\nc. The Egg Bread label does not declare Added Sugars in accordance with 21 CFR 101.9(c)(6) in that the label declares zero grams of added sugar, but light brown sugar is listed as the third most prominent ingredient.\n\nd. The La Torta Bread product label contains a footnote not provided for under 21 CFR 101.9(d)(9).\n\n3. Your Telera (32 oz. and 61 oz.) product is misbranded within the meaning of section 403(i)(1) of the Act [21 U.S.C. 343(i)(1)] in that the product label does not contain an appropriate statement of identity, as required in 21 CFR 101.3(b). “Telera” is a Spanish term and is not an appropriate common or usual name.\n\n4. Your La Torta Bread (72 oz.) and Telera (32 oz. and 61 oz.) products are misbranded within the meaning of section 403(f) of the Act [21 U.S.C. 343(f)] because the product labels provide information in two languages but do not repeat all required information in both languages. For example, both labels include foreign terms in the statement of identities; however, all required labeling is not also provided in the foreign language, as required by 21 CFR 101.15(c)(2).\n\n5. Your Egg Bread (24 oz. and 32 oz.) product is misbranded within the meaning of section 403(g) of the Act [21 U.S.C. 343(g)]. The product appears to be represented as a food for which a definition and standard of identity have been prescribed by regulations as provided by section 401, but it does not appear to conform to such definition and standard in accordance with 21 CFR 136.110. Specifically, egg bread is subject to the standard of identity in 21 CFR 136.110 which requires, among other things, that the food shall contain not less than 2.56 percent of whole egg solids [21 CFR 136.110(e)(2)]; however, this product fails to contain egg as an ingredient.\n\nThis letter is not intended to be an all-inclusive list of the violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal or regulatory action, including without limitation, seizure or injunction.\n\nIn addition to the above violations, we offer the following comments:\n\nThe review of your firm’s product labels was limited to the products and sizes listed above. However, you should conduct a review of all your product labels and make appropriate corrections across all products and product sizes.\n\nWe note that the Telera, La Torta Bread, and Egg Bread products declare “soybean” in a “Food Allergy Contains” statement. If this statement is meant to be a “Contains” statement as provided for under section 403(w) of the Act, then the words “Food Allergy” need to be removed. Additionally, if the ingredient “soybean oil” is the only soy ingredient, and if it is highly refined soybean oil, then is it is not a major food allergen and it should not be declared in the “Contains” statement. You should review your product formulations to ensure all major food allergens and ingredients are declared appropriately.\n\nAs noted above, all the product labels bear the claim “No Trans Fat.” However, FDA has not authorized any nutrient content claims for trans fat, such as “trans fat free,” “no trans fat,” or “zero trans fat.” Under section 403(r)(1)(A) of the Act, a nutrient content claim in food labeling must be made in accordance with a regulation authorizing the use of the claim for the food bearing such a claim not to be misbranded. Although FDA has not defined the term “No Trans Fat” by regulation, we announced in the Federal Register dated July 11, 2003 (68 FR 41507 at 41509) that we would likely consider exercising enforcement discretion for a trans-fat nutrient content claim that is demonstrably true, balanced, adequately substantiated, and not misleading. We point out that, 21 CFR 101.13(i)(3) permits statements about the amount or percentage of a nutrient if the statement does not in any way implicitly characterize the level of the nutrient in the food, and it is not false or misleading in any respect (e.g., \"0 g trans fat”).\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\n1201 Harbor Bay Pkwy\n\nAlameda, CA 94502\n\nRefer to Unique Identification Number 674283 when replying.\n\nIf you would prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification Number in the title of the e-mail message.\n\nIf you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at Elodie.Tong-Lin@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations – West Division 5","California Bread Co.","california-bread-co-674283-04252024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalifornia-bread-co-674283-04252024","2026-10-26T08:08:10.278472+00:00","2024-05-14","674283","Division of Human and Animal Food Operations West V","Mr. Steve S. Shorees, CEO","2026-08-20T00:05:08.955+00:00","2024-04-25",{"id":138,"raw":139,"subject":144,"body_html":145,"body_text":146,"firm_name":147,"letter_id":148,"created_at":108,"fei_number":19,"letter_url":149,"updated_at":150,"action_type":22,"case_status":23,"posted_date":151,"marcs_cms_no":152,"product_type":26,"closeout_date":19,"issuing_office":143,"recipient_name":153,"body_fetched_at":154,"delivery_method":155,"recipient_title":19,"reference_number":19,"action_taken_date":156,"medical_device_id":19,"response_letter_date":19},3201,[140,141,142,143,144,13,13,13],"\u003Ctime datetime=\"2021-08-17T13:20:00Z\">08\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-03T04:00:00Z\">08\u002F03\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fproductos-bredy-usa-llc-614241-08032021\">Productos Bredy USA LLC\u003C\u002Fa>","Division of Southwest Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Samuel Tamez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Co-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Productos Bredy USA LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7601 North Loop East\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Houston\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77028-6017\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Southwest Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 3, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nRe: CMS # 614241\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Tamez:\u003C\u002Fp>\n\n\u003Cp>On March 11 through March 16, 2021, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of Productos Bredy USA LLC located at 7601 North Loop East, Houston, TX 77028-6017. We also conducted an initial inspection on September 24, 2018. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import, including your FSVP for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Soft Drinks from supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You did not develop an FSVP for this product, nor any of the products you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>While you registered to complete training on FSVP and committed to developing FSVPs at the conclusion of the inspection in 2018, you have not developed an FSVP for any of the products you import. We also have not received a response to the Form FDA 483a issued on March 16, 2021.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the food products you import, including your \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;Soft Drinks imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;Soft Drink from supplier&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as well as the other products you import for which you appear to be in violation of Section 805. We may place the foods you import on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that will assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that the foods you import are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Melissa G. Gonzalez, Compliance Officer, the Division of Southwest Imports, 1201 Main Street Suite 7200, Dallas, TX 75202. If you have any questions regarding this letter, you may contact Melissa G. Gonzalez via email at melissag.gonzalez@fda.hhs.gov. Please reference CMS # 614241 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Todd Cato\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Southwest Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nSamuel Tamez\n\nRecipient Title\n\nPresident and Co-Owner\n\nProductos Bredy USA LLC\n\n7601 North Loop East\n\nHouston, TX 77028-6017\n\nUnited States\n\nIssuing Office:\n\nDivision of Southwest Imports\n\nUnited States\n\nAugust 3, 2021\n\nWARNING LETTER\n\nRe: CMS # 614241\n\nDear Mr. Tamez:\n\nOn March 11 through March 16, 2021, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of Productos Bredy USA LLC located at 7601 North Loop East, Houston, TX 77028-6017. We also conducted an initial inspection on September 24, 2018. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import, including your FSVP for (b)(4) Soft Drinks from supplier (b)(4), located in (b)(4). You did not develop an FSVP for this product, nor any of the products you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\n\nWhile you registered to complete training on FSVP and committed to developing FSVPs at the conclusion of the inspection in 2018, you have not developed an FSVP for any of the products you import. We also have not received a response to the Form FDA 483a issued on March 16, 2021.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the food products you import, including your (b)(4) Soft Drinks imported from (b)(4), located in (b)(4).\n\n(b)(3)(A)\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of (b)(4) Soft Drink from supplier (b)(4), located in (b)(4), as well as the other products you import for which you appear to be in violation of Section 805. We may place the foods you import on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that will assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that the foods you import are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Melissa G. Gonzalez, Compliance Officer, the Division of Southwest Imports, 1201 Main Street Suite 7200, Dallas, TX 75202. If you have any questions regarding this letter, you may contact Melissa G. Gonzalez via email at melissag.gonzalez@fda.hhs.gov. Please reference CMS # 614241 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTodd Cato\n\nProgram Division Director\n\nDivision of Southwest Imports","Productos Bredy USA LLC","productos-bredy-usa-llc-614241-08032021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fproductos-bredy-usa-llc-614241-08032021","2026-10-26T08:09:44.640523+00:00","2021-08-17","614241","Samuel Tamez","2026-08-20T02:41:17.742+00:00","Via Express Delivery","2021-08-03",{"id":158,"raw":159,"subject":164,"body_html":165,"body_text":166,"firm_name":167,"letter_id":168,"created_at":169,"fei_number":19,"letter_url":170,"updated_at":171,"action_type":22,"case_status":23,"posted_date":172,"marcs_cms_no":173,"product_type":174,"closeout_date":19,"issuing_office":175,"recipient_name":176,"body_fetched_at":177,"delivery_method":178,"recipient_title":19,"reference_number":19,"action_taken_date":179,"medical_device_id":19,"response_letter_date":19},1725,[160,161,162,163,164,13,13,13],"\u003Ctime datetime=\"2023-11-21T14:20:00Z\">11\u002F21\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-10-26T04:00:00Z\">10\u002F26\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrenntag-great-lakes-llc-660268-10262023\">Brenntag Great Lakes, LLC\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations III ","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Next Day\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Daniel Arneson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Brenntag Great Lakes, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4420 North Harley Davidson Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wauwatosa\u003C\u002Fspan>, \u003Cspan>WI\u003C\u002Fspan> \u003Cspan>53225-4311\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations III \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>10\u002F26\u002F2023\u003Cbr>\n\u003Cstrong>WARNING LETTER\u003Cbr>\nCASE# 660268\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Arneson:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Brenntag Great Lakes, LLC, FEI: 2126821, at N59W14765 Bobolink Avenue, Menomonee Falls, WI 53051-5901, from April 26 to May 5, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drugs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your response and subsequent correspondence to our Form FDA 483. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) hand sanitizer drug product, \u003Cstrong>(b)(4)\u003C\u002Fstrong> 70% Hand Sanitizer Solution, as well as non-drug products including Class 2 solvents and industrial chemicals, including automotive brake parts cleaner using the same equipment. This was noted during a previous inspection and as a corrective action you stated you would discontinue the use of non-dedicated blending tank equipment in the manufacture of OTC drug products. However, our investigator observed that you continued to use non-dedicated blending tank equipment to manufacture OTC drug products. In your response, you explained that while there was a decision to discontinue using non-dedicated tanks, the decision was not effectively communicated to the production team.\u003C\u002Fp>\n\n\u003Cp>It is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture these non-pharmaceutical products due to the risk of cross-contamination. Inadequate removal of active ingredients and product residues from surfaces of non-dedicated manufacturing equipment can lead to contamination of drug products subsequently manufactured on that equipment.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Confirmation of whether you will discontinue manufacturing drugs on shared equipment in your facility and implement appropriate controls to prevent cross-contamination.\u003C\u002Fli>\n\t\u003Cli>If you intend to continue manufacturing both pharmaceutical and non-pharmaceutical products at your facility, provide a plan to show how you will maintain appropriate separation with dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\u003C\u002Fli>\n\t\u003Cli>A review of your production records (e.g. tank logbooks) to determine if other drug products within expiry were made on non-dedicated equipment, and if so, provide a risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Adequate procedures to ensure the QU has the authority to review production records to assure that no errors have occurred or, if errors have occurred, that they have been fully investigated (21 CFR 211.22(a)).\u003C\u002Fli>\n\t\u003Cli>Adequate written procedures for production and process controls (e.g., mixer speed for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Hand Sanitizer Solution) (21 CFR 211.100(a)).\u003C\u002Fli>\n\t\u003Cli>Appropriate control over computer systems (21 CFR 211.68(b)).\u003C\u002Fli>\n\t\u003Cli>Performance of periodic product reviews (21 CFR 211.180(e)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such as your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\n\t\u003Cli>Timelines for completed process performance qualification for marketed drug products for which a state of control has not been adequately\u002Ffully established.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In previous inspections ending on September 10, 2014 and August 2, 2019, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should refer to Case # 660268. Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Brian Nicholson, Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Compliance Officer, Brian Nicholson at (630) 207-9337.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Nicholas F. Lyons\u003Cbr>\nDirector of Compliance\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>For\u003C\u002Fp>\n\n\u003Cp>Jeffrey D. Meng\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cbr>\nKaoni N. Rhodes\u003Cbr>\nRegional Health, Safety, Quality and Environmental Manager\u003Cbr>\nBrenntag Great Lakes, LLC\u003Cbr>\n4420 N. Harley Davidson Avenue\u003Cbr>\nWauwatosa, WI 53225\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Next Day\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Daniel Arneson\n\nRecipient Title\n\nPresident\n\nBrenntag Great Lakes, LLC\n\n4420 North Harley Davidson Avenue\n\nWauwatosa, WI 53225-4311\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\n10\u002F26\u002F2023\n\nWARNING LETTER\n\nCASE# 660268\n\nDear Mr. Arneson:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Brenntag Great Lakes, LLC, FEI: 2126821, at N59W14765 Bobolink Avenue, Menomonee Falls, WI 53051-5901, from April 26 to May 5, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drugs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe acknowledge receipt of your response and subsequent correspondence to our Form FDA 483. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nYour firm manufactures over-the-counter (OTC) hand sanitizer drug product, (b)(4) 70% Hand Sanitizer Solution, as well as non-drug products including Class 2 solvents and industrial chemicals, including automotive brake parts cleaner using the same equipment. This was noted during a previous inspection and as a corrective action you stated you would discontinue the use of non-dedicated blending tank equipment in the manufacture of OTC drug products. However, our investigator observed that you continued to use non-dedicated blending tank equipment to manufacture OTC drug products. In your response, you explained that while there was a decision to discontinue using non-dedicated tanks, the decision was not effectively communicated to the production team.\n\nIt is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture these non-pharmaceutical products due to the risk of cross-contamination. Inadequate removal of active ingredients and product residues from surfaces of non-dedicated manufacturing equipment can lead to contamination of drug products subsequently manufactured on that equipment.\n\nIn response to this letter, provide:\n\nConfirmation of whether you will discontinue manufacturing drugs on shared equipment in your facility and implement appropriate controls to prevent cross-contamination.\n\nIf you intend to continue manufacturing both pharmaceutical and non-pharmaceutical products at your facility, provide a plan to show how you will maintain appropriate separation with dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\n\nA review of your production records (e.g. tank logbooks) to determine if other drug products within expiry were made on non-dedicated equipment, and if so, provide a risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\n\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\nAdequate procedures to ensure the QU has the authority to review production records to assure that no errors have occurred or, if errors have occurred, that they have been fully investigated (21 CFR 211.22(a)).\n\nAdequate written procedures for production and process controls (e.g., mixer speed for (b)(4) Hand Sanitizer Solution) (21 CFR 211.100(a)).\n\nAppropriate control over computer systems (21 CFR 211.68(b)).\n\nPerformance of periodic product reviews (21 CFR 211.180(e)).\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality.\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such as your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\n\nTimelines for completed process performance qualification for marketed drug products for which a state of control has not been adequately\u002Ffully established.\n\nRepeat Observations at Facility\n\nIn previous inspections ending on September 10, 2014 and August 2, 2019, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour response should refer to Case # 660268. Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Brian Nicholson, Compliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations Division III\n\nIf you have questions regarding the contents of this letter, please contact Compliance Officer, Brian Nicholson at (630) 207-9337.\n\nSincerely,\n\n\u002FS\u002F\n\nNicholas F. Lyons\n\nDirector of Compliance\n\nDivision of Pharmaceutical Quality Operations III\n\nFor\n\nJeffrey D. Meng\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations III\n\nCc:\n\nKaoni N. Rhodes\n\nRegional Health, Safety, Quality and Environmental Manager\n\nBrenntag Great Lakes, LLC\n\n4420 N. Harley Davidson Avenue\n\nWauwatosa, WI 53225\n\n____________________\n\n1 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Brenntag Great Lakes, LLC","brenntag-great-lakes-llc-660268-10262023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrenntag-great-lakes-llc-660268-10262023","2026-10-26T08:08:08.858268+00:00","2023-11-21","660268","Drugs","Division of Pharmaceutical Quality Operations III","Mr. Daniel Arneson","2026-08-20T00:29:21.919+00:00","UPS Next Day","2023-10-26",{"id":181,"raw":182,"subject":38,"body_html":186,"body_text":187,"firm_name":188,"letter_id":189,"created_at":128,"fei_number":19,"letter_url":190,"updated_at":191,"action_type":22,"case_status":23,"posted_date":192,"marcs_cms_no":193,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":194,"body_fetched_at":195,"delivery_method":51,"recipient_title":19,"reference_number":196,"action_taken_date":197,"medical_device_id":19,"response_letter_date":19},1257,[183,184,185,37,38,13,13,13],"\u003Ctime datetime=\"2024-09-13T13:00:00Z\">09\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-12T04:00:00Z\">09\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbreeze-smoke-official-692152-09122024\">Breeze Smoke Official\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2402207\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jessica Sons\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Breeze Smoke Official\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>911 N Main Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Monticello\u003C\u002Fspan>, \u003Cspan>IN\u003C\u002Fspan> \u003Cspan>47960\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@breezesmokeofficial.us\"> support@breezesmokeofficial.us\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sonsjessica71@gmail.com\"> sonsjessica71@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 12, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>To Jessica Sons:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fbreezesmokeoffical.us and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Product Without Required Marketing Authorization is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States an ENDS product that lacks a marketing authorization order: Breeze Prime 6000 Puffs Strawberry Apple.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2402207, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>John E. Verbeten\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>WPEngine Inc.\u003Cbr>\nabuse@wpengine.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2402207\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJessica Sons\n\nBreeze Smoke Official\n\n911 N Main Street\n\nMonticello, IN 47960\n\nUnited States\n\nsupport@breezesmokeofficial.us\n\nsonsjessica71@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nSeptember 12, 2024\n\nWARNING LETTER\n\nTo Jessica Sons:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fbreezesmokeoffical.us and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Product Without Required Marketing Authorization is Adulterated and Misbranded\n\nFDA has determined that you offer for sale or distribution to customers in the United States an ENDS product that lacks a marketing authorization order: Breeze Prime 6000 Puffs Strawberry Apple.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2402207, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJohn E. Verbeten\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA Electronic Mail\n\ncc:\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nWPEngine Inc.\n\nabuse@wpengine.com","Breeze Smoke Official","breeze-smoke-official-692152-09122024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbreeze-smoke-official-692152-09122024","2026-10-26T08:08:08.769812+00:00","2024-09-13","692152","Jessica Sons","2026-08-19T23:48:19.061+00:00","RW2402207","2024-09-12",{"id":199,"raw":200,"subject":206,"body_html":207,"body_text":208,"firm_name":209,"letter_id":210,"created_at":128,"fei_number":19,"letter_url":211,"updated_at":212,"action_type":22,"case_status":213,"posted_date":214,"marcs_cms_no":215,"product_type":26,"closeout_date":216,"issuing_office":203,"recipient_name":217,"body_fetched_at":218,"delivery_method":219,"recipient_title":19,"reference_number":19,"action_taken_date":136,"medical_device_id":19,"response_letter_date":19},1246,[201,120,202,203,204,13,205,13],"\u003Ctime datetime=\"2024-09-24T13:20:00Z\">09\u002F24\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrewing-market-coffee-682451-04252024\">Brewing Market Coffee\u003C\u002Fa>","Division of Human and Animal Food Operations West IV","Acidified Foods\u002FEmergency Permit Control\u002FAdulterated\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrewing-market-coffee-682451-07222025\">\u003Ctime datetime=\"2025-12-16T05:00:00Z\">12\u002F16\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","Acidified Foods\u002FEmergency Permit Control\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Artine G. Yapoujian\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u002FPresident\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Brewing Market Coffee\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5775 Arapahoe Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Boulder\u003C\u002Fspan>, \u003Cspan>CO\u003C\u002Fspan> \u003Cspan>80303-1331\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 25, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nRef: CMS Case 682451\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Yapoujian:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your acidified manufacturing facility located at 5775 Arapahoe Ave, Boulder, Colorado from December 14, 2023, through January 25, 2024. During the inspection we collected a finished product sample of Ginger Chai Tea for pH and water activity analysis. The inspection and our sample analysis revealed serious deviations from the Emergency Permit Control regulation, Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108) and Acidified Foods regulations, Title 21, Code of Federal Regulations, Part 114 (21 CFR Part 114).\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, the FDA investigator issued a Form FDA 483, Inspectional Observations, listing the deviations found at your facility. As of the date of this letter, we have not received a written response to the Form FDA 483, Inspectional Observations, issued to you at the close of the inspection.\u003C\u002Fp>\n\n\u003Cp>Accordingly, based on the inspectional findings and sample analysis, we have determined the acidified chai teas manufactured by you are adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (“the Act”) [21 U.S.C. § 342(a)(4)], in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. You can find the Act and applicable regulations through links in FDA’s Internet homepage at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>As an acidified food products processor, you are required to comply with the Act and regulations promulgated under the Act, including those relating to the processing of acidified food products. These regulations are described in 21 CFR Part 108, Emergency Permit Control and in 21 CFR Part 114, Acidified Foods. The Emergency Permit Control regulations were issued, in part, pursuant to Section 404 of the Act [21 U.S.C. § 344]. A temporary emergency permit may be required for acidified foods whenever a processor has failed to fulfill the requirements of 21 CFR Part 108, Subpart, including filing of process information, and the mandatory requirements of 21 CFR Part 114.\u003C\u002Fp>\n\n\u003Cp>You can find the Act, the Emergency Permit Control regulations, and the Acidified Food regulation through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Your significant violations are as follows:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Acidified Foods Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. You failed to provide FDA, no later than 60 days after registration and prior to the packing of a new product, with information on the scheduled process from a qualified person for your new acidified foods as required by 21 CFR 108.25(c)(2). Specifically, there are no scheduled processes on file for shelf-stable chai teas, including but not limited to the Black Tea Chai, in any size or container that your firm produces and distributes.\u003C\u002Fp>\n\n\u003Cp>As a commercial processor engaged in the thermal processing of acidified foods, you must provide the FDA information as to the scheduled processes, including, as necessary, conditions for heat processing and control of pH, salt, sugar, and preservative levels and source and date of the establishment of the process, for each acidified food in each container size as required by 21 CFR 108.25(c)(2).\u003C\u002Fp>\n\n\u003Cp>Further, the scheduled process must be established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidifications and processing of acidified foods, as required by 21 CFR 114.83.\u003C\u002Fp>\n\n\u003Cp>Scheduled process information for acidified foods must be submitted on Form FDA 2541e (Food Process Filing for Acidified Method). More information and registration and filing can be found in the publication \u003Cem>Guidance for Industry: Submitting form FDA 2541 (Food Canning Establishment Registration) and Forms FDA 2541D, FDA 2541e, FDA 2541F, and FDA 2541g (Food Process Filing Forms) to FDA in Electronic or Paper Format\u003C\u002Fem> available at: Guidance for Industry: Submitting Forms for Food Canning Establishment Registration and Food Process Filing to FDA in Electronic or Paper Format | FDA\u003C\u002Fp>\n\n\u003Cp>2. You failed to have operators of processing and packaging systems under the operating supervision of a person who has attended and satisfactorily completed a school approved by the FDA for pH controls and critical factors in acidification, as required by 21 CFR 114.10. Specifically, no one in your facility has attended a Better Process Controls course or any other approved FDA training in the manufacturing of acidified foods.\u003C\u002Fp>\n\n\u003Cp>3. You failed to exercise sufficient control, including frequent testing, and recording of results, so that finished equilibrium pH values for acidified foods are not higher than 4.6, as required by 21 CFR 114.80(a)(2). Specifically, the pH buffers used to calibrate your pH meter are maintained at ambient room temperature. On December 15, 2023, you tested the final pH of your Black Tea Chai drink, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, immediately after heating the drink. The temperature of the drink at the time of the pH measurement was observed to be \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Csup>o\u003C\u002Fsup>F. You did not allow the Black Tea Chai drink to reach ambient room temperature before taking your final pH reading. Additionally, you did not allow the Black Tea Chai drink to reach equilibrium before taking the final pH measurement. You are not measuring the pH of your chai drinks, which are shelf-stable, after they have reached equilibrium.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to Register\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your facility at 5775 Arapahoe Ave, Boulder, Colorado is subject to the food facility registration requirement in section 415 of the Act [21 U.S.C. § 350d], and the implementing regulation at 21 CFR Part 1, Subpart H (21 CFR 1.225-1.243. Section § 415(a)(3) of the Act requires facilities that are required to register with FDA to renew their registrations every other year during the period beginning on October 1 and ending on December 31 of each even-numbered year. Our records indicate, to date, this facility has not renewed their registration with FDA. The failure to register a facility as required is a prohibited act under section 301(dd) of the Act [21 U.S.C. § 331(dd)].\u003C\u002Fp>\n\n\u003Cp>The owner, operator, or agent in charge of your facility, or an individual authorized by this facility’s owner, operator, or agent in charge, must register the facility with FDA within 30 working days of date of this letter. Registration may be accomplished on-line at www.access.fda.gov. As of January 4, 2020, an owner, operator, or agent in charge of a facility must submit their registration to FDA electronically, unless FDA has granted a waiver under 21 CFR 1.245 (see 21 CFR 1.231(a)(2)). If you are submitting a waiver from electronic submission of your registration, you must submit a written request to FDA that explains why it is not reasonable for you to submit a registration electronically to FDA. The waiver request must be submitted in writing to the following address:\u003C\u002Fp>\n\n\u003Cp>U.S. Food and Drug Administration\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\n5001 Campus Dr. (HFS-681)\u003Cbr>\nCollege Park, MD 20740\u003C\u002Fp>\n\n\u003Cp>You must also submit your waiver request by email to FURLS@fda.gov. The waiver request should include the facility name and address and the name of the owner, operator, or agent in charge of the facility.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>In addition to the violations described above, we offer the following comments:\u003C\u002Fstrong>\u003Cbr>\nThe CGMP and PC rule, 21 CFR Part 117, includes updated CGMPs in subpart B with associated requirements for employee training and records in subparts A and F. You are subject to the preventive control requirements in the CGMP &amp; PC rule (primarily located in subparts C and G). Under those requirements, a covered food facility must identify and implement preventive controls to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented and the food manufactured, processed, packed, or held by the facility will not be adulterated under section 402 of the Act [21 U.S.C. § 342].\u003C\u002Fp>\n\n\u003Cp>Further, a covered food facility must have a written food safety that includes a written hazard analysis and written preventive controls that are appropriate to the facility and food (i.e., process controls, food allergen controls, sanitation controls, recall plan, and a supply chain program as necessary). Other requirements include employee training (subpart A) and records (subpart F). Exemptions (21 CFR 117.5) and modified requirements (subpart D) are applicable to certain operations.\u003C\u002Fp>\n\n\u003Cp>Please respond in writing within 15 business days of receipt of this letter, as to the specific steps you have taken to address any violation. Your response should include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be addressed to the U.S. Food and Drug Administration; Attn: Hanna L. Potter, Compliance Officer; 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087 or via email at hanna.potter@fda.hhs.gov. You may reach Ms. Potter at (303) 236-3094 if you have any questions about this matter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>E. Mark Harris\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations – West Division 4\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nArtine G. Yapoujian\n\nRecipient Title\n\nOwner\u002FPresident\n\nBrewing Market Coffee\n\n5775 Arapahoe Ave\n\nBoulder, CO 80303-1331\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West IV\n\nUnited States\n\nApril 25, 2024\n\nWARNING LETTER\n\nRef: CMS Case 682451\n\nDear Mr. Yapoujian:\n\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your acidified manufacturing facility located at 5775 Arapahoe Ave, Boulder, Colorado from December 14, 2023, through January 25, 2024. During the inspection we collected a finished product sample of Ginger Chai Tea for pH and water activity analysis. The inspection and our sample analysis revealed serious deviations from the Emergency Permit Control regulation, Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108) and Acidified Foods regulations, Title 21, Code of Federal Regulations, Part 114 (21 CFR Part 114).\n\nAt the conclusion of the inspection, the FDA investigator issued a Form FDA 483, Inspectional Observations, listing the deviations found at your facility. As of the date of this letter, we have not received a written response to the Form FDA 483, Inspectional Observations, issued to you at the close of the inspection.\n\nAccordingly, based on the inspectional findings and sample analysis, we have determined the acidified chai teas manufactured by you are adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (“the Act”) [21 U.S.C. § 342(a)(4)], in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. You can find the Act and applicable regulations through links in FDA’s Internet homepage at www.fda.gov.\n\nAs an acidified food products processor, you are required to comply with the Act and regulations promulgated under the Act, including those relating to the processing of acidified food products. These regulations are described in 21 CFR Part 108, Emergency Permit Control and in 21 CFR Part 114, Acidified Foods. The Emergency Permit Control regulations were issued, in part, pursuant to Section 404 of the Act [21 U.S.C. § 344]. A temporary emergency permit may be required for acidified foods whenever a processor has failed to fulfill the requirements of 21 CFR Part 108, Subpart, including filing of process information, and the mandatory requirements of 21 CFR Part 114.\n\nYou can find the Act, the Emergency Permit Control regulations, and the Acidified Food regulation through links on FDA’s home page at www.fda.gov.\n\nYour significant violations are as follows:\n\nAcidified Foods Violations\n\n1. You failed to provide FDA, no later than 60 days after registration and prior to the packing of a new product, with information on the scheduled process from a qualified person for your new acidified foods as required by 21 CFR 108.25(c)(2). Specifically, there are no scheduled processes on file for shelf-stable chai teas, including but not limited to the Black Tea Chai, in any size or container that your firm produces and distributes.\n\nAs a commercial processor engaged in the thermal processing of acidified foods, you must provide the FDA information as to the scheduled processes, including, as necessary, conditions for heat processing and control of pH, salt, sugar, and preservative levels and source and date of the establishment of the process, for each acidified food in each container size as required by 21 CFR 108.25(c)(2).\n\nFurther, the scheduled process must be established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidifications and processing of acidified foods, as required by 21 CFR 114.83.\n\nScheduled process information for acidified foods must be submitted on Form FDA 2541e (Food Process Filing for Acidified Method). More information and registration and filing can be found in the publication Guidance for Industry: Submitting form FDA 2541 (Food Canning Establishment Registration) and Forms FDA 2541D, FDA 2541e, FDA 2541F, and FDA 2541g (Food Process Filing Forms) to FDA in Electronic or Paper Format available at: Guidance for Industry: Submitting Forms for Food Canning Establishment Registration and Food Process Filing to FDA in Electronic or Paper Format | FDA\n\n2. You failed to have operators of processing and packaging systems under the operating supervision of a person who has attended and satisfactorily completed a school approved by the FDA for pH controls and critical factors in acidification, as required by 21 CFR 114.10. Specifically, no one in your facility has attended a Better Process Controls course or any other approved FDA training in the manufacturing of acidified foods.\n\n3. You failed to exercise sufficient control, including frequent testing, and recording of results, so that finished equilibrium pH values for acidified foods are not higher than 4.6, as required by 21 CFR 114.80(a)(2). Specifically, the pH buffers used to calibrate your pH meter are maintained at ambient room temperature. On December 15, 2023, you tested the final pH of your Black Tea Chai drink, Lot (b)(4), immediately after heating the drink. The temperature of the drink at the time of the pH measurement was observed to be (b)(4)oF. You did not allow the Black Tea Chai drink to reach ambient room temperature before taking your final pH reading. Additionally, you did not allow the Black Tea Chai drink to reach equilibrium before taking the final pH measurement. You are not measuring the pH of your chai drinks, which are shelf-stable, after they have reached equilibrium.\n\nFailure to Register\n\nFDA has determined that your facility at 5775 Arapahoe Ave, Boulder, Colorado is subject to the food facility registration requirement in section 415 of the Act [21 U.S.C. § 350d], and the implementing regulation at 21 CFR Part 1, Subpart H (21 CFR 1.225-1.243. Section § 415(a)(3) of the Act requires facilities that are required to register with FDA to renew their registrations every other year during the period beginning on October 1 and ending on December 31 of each even-numbered year. Our records indicate, to date, this facility has not renewed their registration with FDA. The failure to register a facility as required is a prohibited act under section 301(dd) of the Act [21 U.S.C. § 331(dd)].\n\nThe owner, operator, or agent in charge of your facility, or an individual authorized by this facility’s owner, operator, or agent in charge, must register the facility with FDA within 30 working days of date of this letter. Registration may be accomplished on-line at www.access.fda.gov. As of January 4, 2020, an owner, operator, or agent in charge of a facility must submit their registration to FDA electronically, unless FDA has granted a waiver under 21 CFR 1.245 (see 21 CFR 1.231(a)(2)). If you are submitting a waiver from electronic submission of your registration, you must submit a written request to FDA that explains why it is not reasonable for you to submit a registration electronically to FDA. The waiver request must be submitted in writing to the following address:\n\nU.S. Food and Drug Administration\n\nCenter for Food Safety and Applied Nutrition\n\n5001 Campus Dr. (HFS-681)\n\nCollege Park, MD 20740\n\nYou must also submit your waiver request by email to FURLS@fda.gov. The waiver request should include the facility name and address and the name of the owner, operator, or agent in charge of the facility.\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nIn addition to the violations described above, we offer the following comments:\n\nThe CGMP and PC rule, 21 CFR Part 117, includes updated CGMPs in subpart B with associated requirements for employee training and records in subparts A and F. You are subject to the preventive control requirements in the CGMP & PC rule (primarily located in subparts C and G). Under those requirements, a covered food facility must identify and implement preventive controls to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented and the food manufactured, processed, packed, or held by the facility will not be adulterated under section 402 of the Act [21 U.S.C. § 342].\n\nFurther, a covered food facility must have a written food safety that includes a written hazard analysis and written preventive controls that are appropriate to the facility and food (i.e., process controls, food allergen controls, sanitation controls, recall plan, and a supply chain program as necessary). Other requirements include employee training (subpart A) and records (subpart F). Exemptions (21 CFR 117.5) and modified requirements (subpart D) are applicable to certain operations.\n\nPlease respond in writing within 15 business days of receipt of this letter, as to the specific steps you have taken to address any violation. Your response should include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be addressed to the U.S. Food and Drug Administration; Attn: Hanna L. Potter, Compliance Officer; 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087 or via email at hanna.potter@fda.hhs.gov. You may reach Ms. Potter at (303) 236-3094 if you have any questions about this matter.\n\nSincerely,\n\n\u002FS\u002F\n\nE. Mark Harris\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations – West Division 4","Brewing Market Coffee","brewing-market-coffee-682451-04252024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrewing-market-coffee-682451-04252024","2026-10-26T08:08:08.994298+00:00","Closed Out","2024-09-24","682451","2025-12-16","Artine G. Yapoujian","2026-08-19T23:32:54.335+00:00","VIA UPS",{"id":221,"raw":222,"subject":38,"body_html":226,"body_text":227,"firm_name":228,"letter_id":229,"created_at":78,"fei_number":19,"letter_url":230,"updated_at":231,"action_type":22,"case_status":23,"posted_date":232,"marcs_cms_no":233,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":234,"body_fetched_at":235,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":232,"medical_device_id":19,"response_letter_date":19},2713,[223,224,225,37,38,13,13,13],"\u003Ctime datetime=\"2022-05-02T19:00:00Z\">05\u002F02\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-02T04:00:00Z\">05\u002F02\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbreathe-easy-vapes-lp-dba-breathe-easy-vapes-631568-05022022\">Breathe Easy Vapes, LP dba Breathe Easy Vapes\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Nathaniel Hamby\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Breathe Easy Vapes, LP dba Breathe Easy Vapes\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1966 South Main Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Weatherford\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76086\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sfields.breatheeasy@gmail.com\"> sfields.breatheeasy@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 2, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Hamby:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Breathe Easy Vapes manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Breathe Easy Vapes MELON BERRY 6 mg e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 5,100 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200528, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\nSamantha Griffith\u003Cbr>\nsam@breatheeasyvapes.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nNathaniel Hamby\n\nRecipient Title\n\nOwner\n\nBreathe Easy Vapes, LP dba Breathe Easy Vapes\n\n1966 South Main Street\n\nWeatherford, TX 76086\n\nUnited States\n\nsfields.breatheeasy@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMay 2, 2022\n\nWARNING LETTER\n\nDear Mr. Hamby:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Breathe Easy Vapes manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Breathe Easy Vapes MELON BERRY 6 mg e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 5,100 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200528, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\ncc:\n\nSamantha Griffith\n\nsam@breatheeasyvapes.com","Breathe Easy Vapes, LP dba Breathe Easy Vapes","breathe-easy-vapes-lp-dba-breathe-easy-vapes-631568-05022022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbreathe-easy-vapes-lp-dba-breathe-easy-vapes-631568-05022022","2026-10-26T08:08:08.685107+00:00","2022-05-02","631568","Nathaniel Hamby","2026-08-20T01:57:59.303+00:00",12,{"510k":238,"classification":239,"enforcement":240,"event":241,"event_backfill":242,"pma":243,"warning_letter":244},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-20T04:00:32.497+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]